WO2018181294A1 - 医薬製剤 - Google Patents
医薬製剤 Download PDFInfo
- Publication number
- WO2018181294A1 WO2018181294A1 PCT/JP2018/012403 JP2018012403W WO2018181294A1 WO 2018181294 A1 WO2018181294 A1 WO 2018181294A1 JP 2018012403 W JP2018012403 W JP 2018012403W WO 2018181294 A1 WO2018181294 A1 WO 2018181294A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound represented
- salt
- general formula
- solvate
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 37
- 150000001875 compounds Chemical class 0.000 claims abstract description 175
- 150000003839 salts Chemical class 0.000 claims abstract description 159
- 239000012453 solvate Substances 0.000 claims abstract description 144
- 239000000203 mixture Substances 0.000 claims abstract description 129
- -1 prostaglandin compound Chemical class 0.000 claims abstract description 71
- 239000002253 acid Substances 0.000 claims abstract description 38
- 229920005672 polyolefin resin Polymers 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 32
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 30
- 239000004094 surface-active agent Substances 0.000 claims abstract description 30
- 125000001424 substituent group Chemical group 0.000 claims abstract description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 10
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims abstract description 10
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims abstract description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 10
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 37
- 150000003180 prostaglandins Chemical class 0.000 claims description 37
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 30
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 28
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 28
- 150000007513 acids Chemical class 0.000 claims description 27
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 claims description 27
- 229960003511 macrogol Drugs 0.000 claims description 25
- 239000004743 Polypropylene Substances 0.000 claims description 24
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 24
- 239000004327 boric acid Substances 0.000 claims description 24
- 229920001155 polypropylene Polymers 0.000 claims description 24
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 22
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 22
- 235000010355 mannitol Nutrition 0.000 claims description 22
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 21
- 229960001160 latanoprost Drugs 0.000 claims description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims description 18
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims description 18
- 229960002368 travoprost Drugs 0.000 claims description 18
- 229960002470 bimatoprost Drugs 0.000 claims description 17
- 229930195725 Mannitol Natural products 0.000 claims description 16
- 239000000594 mannitol Substances 0.000 claims description 16
- WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 claims description 15
- 229960004458 tafluprost Drugs 0.000 claims description 14
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims description 13
- 229940073464 benzododecinium bromide Drugs 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 239000004698 Polyethylene Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229920000573 polyethylene Polymers 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 235000010356 sorbitol Nutrition 0.000 claims description 6
- 235000013772 propylene glycol Nutrition 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 22
- 238000002360 preparation method Methods 0.000 abstract description 2
- 235000002639 sodium chloride Nutrition 0.000 description 165
- OURRXQUGYQRVML-AREMUKBSSA-N [4-[(2s)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate Chemical compound CC1=CC(C)=CC=C1C(=O)OCC1=CC=C([C@@H](CN)C(=O)NC=2C=C3C=CN=CC3=CC=2)C=C1 OURRXQUGYQRVML-AREMUKBSSA-N 0.000 description 40
- 238000012360 testing method Methods 0.000 description 35
- 229950009210 netarsudil Drugs 0.000 description 34
- 235000010338 boric acid Nutrition 0.000 description 33
- 238000004519 manufacturing process Methods 0.000 description 22
- 238000001179 sorption measurement Methods 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 238000003860 storage Methods 0.000 description 15
- 208000010412 Glaucoma Diseases 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 239000008213 purified water Substances 0.000 description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 11
- 125000005619 boric acid group Chemical group 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 10
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 10
- 239000003889 eye drop Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 230000000144 pharmacologic effect Effects 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 229920001903 high density polyethylene Polymers 0.000 description 8
- 239000004700 high-density polyethylene Substances 0.000 description 8
- 235000011007 phosphoric acid Nutrition 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Substances [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 229920001577 copolymer Polymers 0.000 description 7
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000006096 absorbing agent Substances 0.000 description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 6
- 235000019799 monosodium phosphate Nutrition 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 206010030043 Ocular hypertension Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229920001684 low density polyethylene Polymers 0.000 description 5
- 239000004702 low-density polyethylene Substances 0.000 description 5
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
- 239000005977 Ethylene Substances 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000003732 agents acting on the eye Substances 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 150000003863 ammonium salts Chemical class 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 229940125702 ophthalmic agent Drugs 0.000 description 4
- 150000003016 phosphoric acids Chemical class 0.000 description 4
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 238000007614 solvation Methods 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 3
- VDYRZXYYQMMFJW-UHFFFAOYSA-N 2-(dimethylamino)-n-(1-oxo-2h-isoquinolin-6-yl)-2-thiophen-3-ylacetamide Chemical compound C=1C=C2C(O)=NC=CC2=CC=1NC(=O)C(N(C)C)C=1C=CSC=1 VDYRZXYYQMMFJW-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 3
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 229920000098 polyolefin Polymers 0.000 description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000000568 rho-Associated Kinases Human genes 0.000 description 3
- 108010041788 rho-Associated Kinases Proteins 0.000 description 3
- 229960002668 sodium chloride Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 229960004605 timolol Drugs 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- WMFHUUKYIUOHRA-UHFFFAOYSA-N (3-phenoxyphenyl)methanamine;hydrochloride Chemical compound Cl.NCC1=CC=CC(OC=2C=CC=CC=2)=C1 WMFHUUKYIUOHRA-UHFFFAOYSA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- ZMWRRFHBXARRRT-UHFFFAOYSA-N 2-(benzotriazol-2-yl)-4,6-bis(2-methylbutan-2-yl)phenol Chemical compound CCC(C)(C)C1=CC(C(C)(C)CC)=CC(N2N=C3C=CC=CC3=N2)=C1O ZMWRRFHBXARRRT-UHFFFAOYSA-N 0.000 description 2
- OLFNXLXEGXRUOI-UHFFFAOYSA-N 2-(benzotriazol-2-yl)-4,6-bis(2-phenylpropan-2-yl)phenol Chemical compound C=1C(N2N=C3C=CC=CC3=N2)=C(O)C(C(C)(C)C=2C=CC=CC=2)=CC=1C(C)(C)C1=CC=CC=C1 OLFNXLXEGXRUOI-UHFFFAOYSA-N 0.000 description 2
- IYAZLDLPUNDVAG-UHFFFAOYSA-N 2-(benzotriazol-2-yl)-4-(2,4,4-trimethylpentan-2-yl)phenol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(O)C(N2N=C3C=CC=CC3=N2)=C1 IYAZLDLPUNDVAG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- WSSSPWUEQFSQQG-UHFFFAOYSA-N 4-methyl-1-pentene Chemical compound CC(C)CC=C WSSSPWUEQFSQQG-UHFFFAOYSA-N 0.000 description 2
- UWSMKYBKUPAEJQ-UHFFFAOYSA-N 5-Chloro-2-(3,5-di-tert-butyl-2-hydroxyphenyl)-2H-benzotriazole Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=CC(N2N=C3C=C(Cl)C=CC3=N2)=C1O UWSMKYBKUPAEJQ-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- VJCCWFNUFSJBNG-UHFFFAOYSA-N NCC(C(Nc(cc1)cc2c1cncc2)=O)c(cc1)ccc1Cl Chemical compound NCC(C(Nc(cc1)cc2c1cncc2)=O)c(cc1)ccc1Cl VJCCWFNUFSJBNG-UHFFFAOYSA-N 0.000 description 2
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 2
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- OCWYEMOEOGEQAN-UHFFFAOYSA-N bumetrizole Chemical compound CC(C)(C)C1=CC(C)=CC(N2N=C3C=C(Cl)C=CC3=N2)=C1O OCWYEMOEOGEQAN-UHFFFAOYSA-N 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 2
- MQRJBSHKWOFOGF-UHFFFAOYSA-L disodium;carbonate;hydrate Chemical compound O.[Na+].[Na+].[O-]C([O-])=O MQRJBSHKWOFOGF-UHFFFAOYSA-L 0.000 description 2
- LVXHNCUCBXIIPE-UHFFFAOYSA-L disodium;hydrogen phosphate;hydrate Chemical compound O.[Na+].[Na+].OP([O-])([O-])=O LVXHNCUCBXIIPE-UHFFFAOYSA-L 0.000 description 2
- MCPKSFINULVDNX-UHFFFAOYSA-N drometrizole Chemical compound CC1=CC=C(O)C(N2N=C3C=CC=CC3=N2)=C1 MCPKSFINULVDNX-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000011147 magnesium chloride Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 2
- QUAMTGJKVDWJEQ-UHFFFAOYSA-N octabenzone Chemical compound OC1=CC(OCCCCCCCC)=CC=C1C(=O)C1=CC=CC=C1 QUAMTGJKVDWJEQ-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 229960001416 pilocarpine Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000001433 sodium tartrate Substances 0.000 description 2
- 229960002167 sodium tartrate Drugs 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 2
- 235000019801 trisodium phosphate Nutrition 0.000 description 2
- 229950006594 verosudil Drugs 0.000 description 2
- DTGKSKDOIYIVQL-NQMVMOMDSA-N (+)-Borneol Natural products C1C[C@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-NQMVMOMDSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- SXFBQAMLJMDXOD-UHFFFAOYSA-N (+)-hydrogentartrate bitartrate salt Chemical compound OC(=O)C(O)C(O)C(O)=O.OC(=O)C(O)C(O)C(O)=O SXFBQAMLJMDXOD-UHFFFAOYSA-N 0.000 description 1
- ZNMXKJDERFMXNF-ZETCQYMHSA-N (1r)-1-(2-hydroxy-1,3,2-benzodioxaborol-5-yl)-2-(methylamino)ethanol Chemical compound CNC[C@H](O)C1=CC=C2OB(O)OC2=C1 ZNMXKJDERFMXNF-ZETCQYMHSA-N 0.000 description 1
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 description 1
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
- FBZQBGYPONNWCG-UHFFFAOYSA-N (4,5-dihydroxy-2,3-dimethoxyphenyl)-phenylmethanone Chemical compound COC1=C(O)C(O)=CC(C(=O)C=2C=CC=CC=2)=C1OC FBZQBGYPONNWCG-UHFFFAOYSA-N 0.000 description 1
- RLKHJWGQKCJXPV-UHFFFAOYSA-N (4,5-dihydroxy-2,3-dimethoxyphenyl)-phenylmethanone;sodium Chemical compound [Na].COC1=C(O)C(O)=CC(C(=O)C=2C=CC=CC=2)=C1OC RLKHJWGQKCJXPV-UHFFFAOYSA-N 0.000 description 1
- KMCRQJMZUHNLKJ-NSCUHMNNSA-N (e)-4-(4-nitrophenyl)but-3-en-2-one Chemical compound CC(=O)\C=C\C1=CC=C([N+]([O-])=O)C=C1 KMCRQJMZUHNLKJ-NSCUHMNNSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- NAQWICRLNQSPPW-UHFFFAOYSA-N 1,2,3,4-tetrachloronaphthalene Chemical compound C1=CC=CC2=C(Cl)C(Cl)=C(Cl)C(Cl)=C21 NAQWICRLNQSPPW-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- CVSXFBFIOUYODT-UHFFFAOYSA-N 178671-58-4 Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)=C(C#N)C(=O)OCC(COC(=O)C(C#N)=C(C=1C=CC=CC=1)C=1C=CC=CC=1)(COC(=O)C(C#N)=C(C=1C=CC=CC=1)C=1C=CC=CC=1)COC(=O)C(C#N)=C(C=1C=CC=CC=1)C1=CC=CC=C1 CVSXFBFIOUYODT-UHFFFAOYSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- LJINSKIHVMGTDJ-UHFFFAOYSA-N 2-(2,2-diaminoethylamino)acetic acid Chemical compound NC(N)CNCC(O)=O LJINSKIHVMGTDJ-UHFFFAOYSA-N 0.000 description 1
- LEVFXWNQQSSNAC-UHFFFAOYSA-N 2-(4,6-diphenyl-1,3,5-triazin-2-yl)-5-hexoxyphenol Chemical compound OC1=CC(OCCCCCC)=CC=C1C1=NC(C=2C=CC=CC=2)=NC(C=2C=CC=CC=2)=N1 LEVFXWNQQSSNAC-UHFFFAOYSA-N 0.000 description 1
- LHPPDQUVECZQSW-UHFFFAOYSA-N 2-(benzotriazol-2-yl)-4,6-ditert-butylphenol Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=CC(N2N=C3C=CC=CC3=N2)=C1O LHPPDQUVECZQSW-UHFFFAOYSA-N 0.000 description 1
- VQMHSKWEJGIXGA-UHFFFAOYSA-N 2-(benzotriazol-2-yl)-6-dodecyl-4-methylphenol Chemical compound CCCCCCCCCCCCC1=CC(C)=CC(N2N=C3C=CC=CC3=N2)=C1O VQMHSKWEJGIXGA-UHFFFAOYSA-N 0.000 description 1
- FQNKTJPBXAZUGC-UHFFFAOYSA-N 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoic acid Chemical compound OC1=CC(N(CC)CC)=CC=C1C(=O)C1=CC=CC=C1C(O)=O FQNKTJPBXAZUGC-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 1
- YTZPUTADNGREHA-UHFFFAOYSA-N 2h-benzo[e]benzotriazole Chemical compound C1=CC2=CC=CC=C2C2=NNN=C21 YTZPUTADNGREHA-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- YKFROQCFVXOUPW-UHFFFAOYSA-N 4-(methylthio) aniline Chemical compound CSC1=CC=C(N)C=C1 YKFROQCFVXOUPW-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- RHLJLALHBZGAFM-UHFFFAOYSA-N Bunazosinum Chemical compound C1CN(C(=O)CCC)CCCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 RHLJLALHBZGAFM-UHFFFAOYSA-N 0.000 description 1
- JKWWJINLSQEIMJ-UHFFFAOYSA-N C(C)(=O)O.[Na].C(C)(=O)OC(C)=O Chemical compound C(C)(=O)O.[Na].C(C)(=O)OC(C)=O JKWWJINLSQEIMJ-UHFFFAOYSA-N 0.000 description 1
- GXHOZULSUHZWFB-UHFFFAOYSA-N C(C=1C(O)=CC=CC1)(=O)O.C(C=1C(O)=CC=CC1)(=O)O.C=CC.C=CC Chemical compound C(C=1C(O)=CC=CC1)(=O)O.C(C=1C(O)=CC=CC1)(=O)O.C=CC.C=CC GXHOZULSUHZWFB-UHFFFAOYSA-N 0.000 description 1
- DVXXVPLJCIUDSL-UHFFFAOYSA-N CN(C(C(=O)NC=1C=C2C=CNC(C2=CC1)=O)C1=CSC=C1)C.C(C)(=O)N Chemical compound CN(C(C(=O)NC=1C=C2C=CNC(C2=CC1)=O)C1=CSC=C1)C.C(C)(=O)N DVXXVPLJCIUDSL-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 239000004132 Calcium polyphosphate Substances 0.000 description 1
- 239000004136 Calcium sodium polyphosphate Substances 0.000 description 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 239000004716 Ethylene/acrylic acid copolymer Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- OMCPLEZZPVJJIS-UHFFFAOYSA-N Hypadil (TN) Chemical compound C1C(O[N+]([O-])=O)COC2=C1C=CC=C2OCC(O)CNC(C)C OMCPLEZZPVJJIS-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- QIJRTFXNRTXDIP-JIZZDEOASA-N L-cysteine hydrochloride hydrate Chemical compound O.Cl.SC[C@H](N)C(O)=O QIJRTFXNRTXDIP-JIZZDEOASA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010067013 Normal tension glaucoma Diseases 0.000 description 1
- VHSSESVAKURAGI-UHFFFAOYSA-N OP(O)(=O)OP(O)(O)=O.OP(O)(=O)OP(O)(O)=O Chemical compound OP(O)(=O)OP(O)(O)=O.OP(O)(=O)OP(O)(O)=O VHSSESVAKURAGI-UHFFFAOYSA-N 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- YYVFXSYQSOZCOQ-UHFFFAOYSA-N Oxyquinoline sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C[NH+]=C2C(O)=CC=CC2=C1.C1=C[NH+]=C2C(O)=CC=CC2=C1 YYVFXSYQSOZCOQ-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- OCULZZQWCIGXQR-UHFFFAOYSA-N [3-(benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl] propanoate Chemical compound CC(C)(C)C1=CC(OC(=O)CC)=CC(N2N=C3C=CC=CC3=N2)=C1O OCULZZQWCIGXQR-UHFFFAOYSA-N 0.000 description 1
- QQDRLKRHJOAQDC-FBHGDYMESA-N [4-[(2s)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CC1=CC(C)=CC=C1C(=O)OCC1=CC=C([C@@H](CN)C(=O)NC=2C=C3C=CN=CC3=CC=2)C=C1 QQDRLKRHJOAQDC-FBHGDYMESA-N 0.000 description 1
- RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 description 1
- HEAFLBOWLRRIHV-UHFFFAOYSA-N [Na].[P] Chemical compound [Na].[P] HEAFLBOWLRRIHV-UHFFFAOYSA-N 0.000 description 1
- VPNXJUJQURCEAB-UHFFFAOYSA-K [O-]P([O-])([O-])=O.P.[Ca+2].[Ca+2] Chemical compound [O-]P([O-])([O-])=O.P.[Ca+2].[Ca+2] VPNXJUJQURCEAB-UHFFFAOYSA-K 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 201000001326 acute closed-angle glaucoma Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 239000001518 benzyl (E)-3-phenylprop-2-enoate Substances 0.000 description 1
- IUGQFMIATSVYLK-UHFFFAOYSA-N benzyl 2-(4-hydroxyphenyl)acetate Chemical compound C1=CC(O)=CC=C1CC(=O)OCC1=CC=CC=C1 IUGQFMIATSVYLK-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- NGHOLYJTSCBCGC-QXMHVHEDSA-N benzyl cinnamate Chemical compound C=1C=CC=CC=1\C=C/C(=O)OCC1=CC=CC=C1 NGHOLYJTSCBCGC-QXMHVHEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- 229960004347 betaxolol hydrochloride Drugs 0.000 description 1
- SODJJEXAWOSSON-UHFFFAOYSA-N bis(2-hydroxy-4-methoxyphenyl)methanone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=C(OC)C=C1O SODJJEXAWOSSON-UHFFFAOYSA-N 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 229960001724 brimonidine tartrate Drugs 0.000 description 1
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 1
- 229960000722 brinzolamide Drugs 0.000 description 1
- 229960002467 bunazosin Drugs 0.000 description 1
- 229960003612 bunazosin hydrochloride Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- NEEHYRZPVYRGPP-IYEMJOQQSA-L calcium gluconate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O NEEHYRZPVYRGPP-IYEMJOQQSA-L 0.000 description 1
- 235000019827 calcium polyphosphate Nutrition 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 235000019348 calcium sodium polyphosphate Nutrition 0.000 description 1
- MDAVASCOAJMZHZ-UHFFFAOYSA-L calcium;2-hydroxypropanoate;hydrate Chemical compound O.[Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MDAVASCOAJMZHZ-UHFFFAOYSA-L 0.000 description 1
- ZBZJARSYCHAEND-UHFFFAOYSA-L calcium;dihydrogen phosphate;hydrate Chemical compound O.[Ca+2].OP(O)([O-])=O.OP(O)([O-])=O ZBZJARSYCHAEND-UHFFFAOYSA-L 0.000 description 1
- HUSUHZRVLBSGBO-UHFFFAOYSA-L calcium;dihydrogen phosphate;hydroxide Chemical compound O.[Ca+2].OP([O-])([O-])=O HUSUHZRVLBSGBO-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- FYBXRCFPOTXTJF-UHFFFAOYSA-N carteolol hydrochloride Chemical compound [Cl-].N1C(=O)CCC2=C1C=CC=C2OCC(O)C[NH2+]C(C)(C)C FYBXRCFPOTXTJF-UHFFFAOYSA-N 0.000 description 1
- 229960002165 carteolol hydrochloride Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 201000005682 chronic closed-angle glaucoma Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- NGHOLYJTSCBCGC-UHFFFAOYSA-N cis-cinnamic acid benzyl ester Natural products C=1C=CC=CC=1C=CC(=O)OCC1=CC=CC=C1 NGHOLYJTSCBCGC-UHFFFAOYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 229960001270 d- tartaric acid Drugs 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 229960005081 diclofenamide Drugs 0.000 description 1
- GJQPMPFPNINLKP-UHFFFAOYSA-N diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 description 1
- OCUJLLGVOUDECM-UHFFFAOYSA-N dipivefrin Chemical compound CNCC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 OCUJLLGVOUDECM-UHFFFAOYSA-N 0.000 description 1
- VKFAUCPBMAGVRG-UHFFFAOYSA-N dipivefrin hydrochloride Chemical compound [Cl-].C[NH2+]CC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 VKFAUCPBMAGVRG-UHFFFAOYSA-N 0.000 description 1
- 229940090570 dipivefrin hydrochloride Drugs 0.000 description 1
- 229960000966 dipivefrine Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- IKALZAKZWHFNIC-JIZZDEOASA-L dipotassium;(2s)-2-aminobutanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O IKALZAKZWHFNIC-JIZZDEOASA-L 0.000 description 1
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- MCYYJHPHBOPLMH-UHFFFAOYSA-L disodium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane;hydrate Chemical compound O.[Na+].[Na+].[O-]S([O-])(=O)=S MCYYJHPHBOPLMH-UHFFFAOYSA-L 0.000 description 1
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229950010030 dl-alanine Drugs 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
- OSRUSFPMRGDLAG-QMGYSKNISA-N dorzolamide hydrochloride Chemical compound [Cl-].CC[NH2+][C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 OSRUSFPMRGDLAG-QMGYSKNISA-N 0.000 description 1
- 229960002506 dorzolamide hydrochloride Drugs 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 1
- 229960000655 ensulizole Drugs 0.000 description 1
- 229960003072 epinephrine hydrochloride Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- IAJNXBNRYMEYAZ-UHFFFAOYSA-N ethyl 2-cyano-3,3-diphenylprop-2-enoate Chemical compound C=1C=CC=CC=1C(=C(C#N)C(=O)OCC)C1=CC=CC=C1 IAJNXBNRYMEYAZ-UHFFFAOYSA-N 0.000 description 1
- 229920006242 ethylene acrylic acid copolymer Polymers 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229960002350 guaiazulen Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- KPSZWAJWFMFMFF-UHFFFAOYSA-N hept-5-enoic acid Chemical compound CC=CCCCC(O)=O KPSZWAJWFMFMFF-UHFFFAOYSA-N 0.000 description 1
- 150000004688 heptahydrates Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229920000092 linear low density polyethylene Polymers 0.000 description 1
- 239000004707 linear low-density polyethylene Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000002978 low tension glaucoma Diseases 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 description 1
- NFFJLMKHRCXLJO-DKWTVANSSA-L magnesium;(2s)-2-aminobutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O NFFJLMKHRCXLJO-DKWTVANSSA-L 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920001179 medium density polyethylene Polymers 0.000 description 1
- 239000004701 medium-density polyethylene Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- PVWXTVUZGJXFJQ-UHFFFAOYSA-N methyl 4-methyl-3-phenyl-2-propan-2-ylpent-2-enoate Chemical compound COC(=O)C(C(C)C)=C(C(C)C)C1=CC=CC=C1 PVWXTVUZGJXFJQ-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 229950000754 nipradilol Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229950002083 octabenzone Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 229960003921 octisalate Drugs 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical compound C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960001257 oxyquinoline sulfate Drugs 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- LYKRPDCJKSXAHS-UHFFFAOYSA-N phenyl-(2,3,4,5-tetrahydroxyphenyl)methanone Chemical compound OC1=C(O)C(O)=CC(C(=O)C=2C=CC=CC=2)=C1O LYKRPDCJKSXAHS-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 229960001963 pilocarpine nitrate Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229960004109 potassium acetate Drugs 0.000 description 1
- 229960004839 potassium iodide Drugs 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 201000006366 primary open angle glaucoma Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- QSKQVZWVLOIIEV-NSHDSACASA-N ripasudil Chemical compound C[C@H]1CNCCCN1S(=O)(=O)C1=CC=CC2=CN=CC(F)=C12 QSKQVZWVLOIIEV-NSHDSACASA-N 0.000 description 1
- 229950007455 ripasudil Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229920006300 shrink film Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940006186 sodium polystyrene sulfonate Drugs 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- HLWRUJAIJJEZDL-UHFFFAOYSA-M sodium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC([O-])=O HLWRUJAIJJEZDL-UHFFFAOYSA-M 0.000 description 1
- KZQSXALQTHVPDQ-UHFFFAOYSA-M sodium;butanedioate;hydron Chemical compound [Na+].OC(=O)CCC([O-])=O KZQSXALQTHVPDQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical class C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- WYXIGTJNYDDFFH-UHFFFAOYSA-Q triazanium;borate Chemical compound [NH4+].[NH4+].[NH4+].[O-]B([O-])[O-] WYXIGTJNYDDFFH-UHFFFAOYSA-Q 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 229950008081 unoprostone isopropyl Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1468—Containers characterised by specific material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Definitions
- the present invention relates to pharmaceutical preparations and the like.
- network may also be referred to as AR-13324, which has pharmacological actions such as Rho kinase inhibitory action and norepinephrine transporter inhibitory action, such as ocular hypertension and glaucoma. It is reported to be useful for the prevention and treatment of eye diseases (for example, Patent Document 1, Non-Patent Documents 1 and 2).
- verosil may also be referred to as AR-12286, which has a Rho kinase inhibitory action and is used for the prevention and treatment of ocular diseases such as ocular hypertension. It is reported to be useful (for example, Patent Document 2, Non-Patent Documents 1 and 3). Therefore, it is extremely useful to establish a technique for stably formulating these isoquinoline-6-amino derivatives as, for example, ophthalmic agents.
- Patent Document 3 describes that a composition containing netersil or velosil was prepared in a 150 mL plastic container.
- each composition is prepared for use in a pharmacological test, and there is no description about the stability of netersil or velosil in the composition. There is no mention of any materials or properties.
- the object of the present invention is to establish a technique for stably formulating isoquinoline-6-amino derivatives such as netersil and velosil as ophthalmic agents and the like.
- An ophthalmic agent or the like is usually a composition containing water (aqueous composition). Accordingly, the present inventor prepared an aqueous composition containing an isoquinoline-6-amino derivative such as netersudil and placed it in a polyolefin resin container to confirm its storage stability. However, surprisingly, it was revealed that the content of isoquinoline-6-amino derivative, which is presumed to be caused by adsorption to the resin, is reduced by storage under high temperature conditions. In view of this, the present inventor has further studied diligently to suppress a decrease in the content of the isoquinoline-6-amino derivative in the aqueous composition.
- the aqueous composition containing the isoquinoline-6-amino derivative is further added with one or more components selected from the group consisting of acids, quaternary ammonium surfactants, polyhydric alcohols, and prostaglandins.
- the present invention has been completed by discovering that it can be contained and contained in a polyolefin-based resin container so that a decrease in the content is suppressed and the pharmaceutical preparation has improved stability.
- the present invention includes the following components (A) and (B): (A) The following general formula (1)
- R 1 and R 2 each independently represent a hydrogen atom or a C 1 -C 4 alkyl group
- R 3 represents a hydrogen atom or a hydroxy group
- A is —CH (R 4 ) — or —CH 2 —CH (R 4 ) —
- R 4 may have a C 6 -C 10 aryl group which may have a substituent, or may have a substituent).
- the tautomer is also contained in Formula (1).
- a pharmaceutical composition is provided in which an aqueous composition containing is contained in a polyolefin resin container.
- the stability of an isoquinoline-6-amino derivative typified by Netersudil in an aqueous composition can be improved.
- R 1 and R 2 each independently represent a hydrogen atom or a C 1 -C 4 alkyl group
- R 3 represents a hydrogen atom or a hydroxy group
- A is —CH (R 4 ) — or —CH 2 —CH (R 4 ) —
- R 4 may have a C 6 -C 10 aryl group which may have a substituent, or may have a substituent).
- the tautomer is also contained in Formula (1).
- a salt or a solvate thereof is also included in the compound represented by the formula (1) or a salt thereof or a solvate thereof.
- the salt of the compound represented by the general formula (1) is not particularly limited as long as it is a pharmaceutically acceptable salt, and specifically, for example, hydrochloride, sulfate, nitrate, hydrofluoric acid.
- Inorganic acid salts such as salt and hydrobromide; acetate, tartrate, lactate, citrate, fumarate, maleate, succinate, methanesulfonate, ethanesulfonate, benzenesulfone
- Organic acid salts such as acid salts, toluene sulfonates, naphthalene sulfonates, camphor sulfonates, and the like can be mentioned, and hydrochlorides and methane sulfonates are preferred.
- Examples of the solvate of the compound represented by the general formula (1) or a salt thereof include hydrates and alcohol solvates.
- various stereoisomers may exist, but as the compound represented by the general formula (1),
- the configuration is not particularly limited, and may be a single stereoisomer or a mixture of various stereoisomers in any ratio.
- a compound represented by various formulas has an asymmetric carbon in its chemical structure, such a formula is represented by various stereoisomers alone and those unless otherwise specified. Includes all mixtures in any proportion. Therefore, the compound represented by the formula that does not particularly specify the configuration may be a single stereoisomer or a mixture of various stereoisomers in an arbitrary ratio.
- the general formula (1) includes not only the compound directly represented by the general formula (1) but also tautomers thereof. Specifically, for example, in the case of the following general formula (1a) in which R 3 is a hydroxy group, its tautomer (general formula (1b)) may be produced. In addition to the compound represented by the following general formula (1a), a compound represented by the general formula (1b) is also included in the “compound”.
- the “C 1 -C 4 alkyl group” means a linear, branched or cyclic alkyl group having 1 to 4 carbon atoms. Specific examples of the “C 1 -C 4 alkyl group” include methyl group, ethyl group, n-propyl group, isopropyl group, cyclopropyl group, n-butyl group, t-butyl group, isobutyl group and the like. And a methyl group is preferable.
- the “C 6 -C 10 aryl group” means an aryl group having 6 to 10 carbon atoms. Specific examples of the “C 6 -C 10 aryl group” include a phenyl group and a naphthyl group, and a phenyl group is preferable.
- the “5- to 10-membered heteroaryl group” refers to a 5- to 10-membered monocyclic group containing 1 to 4 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom as ring constituent atoms. Means a polycyclic or fused-ring aromatic heterocyclic group.
- “5- to 10-membered heteroaryl group” include furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl Group, triazolyl group, tetrazolyl group, pyridyl group, pyrimidyl group, pyrazinyl group, pyridazinyl group, benzofuranyl group, isobenzofuranyl group, benzothienyl group, indolyl group, isoindolyl group, indazolyl group, benzimidazolyl group, benzoxazolyl group , Benzoisoxazolyl group, benzothiazolyl group, benzoisothiazolyl group, benzoxiadiazolyl group, benzothiadiazolyl group, benzotriazolyl
- the “substituent” in the “optionally substituted C 6 -C 10 aryl group” and the “optionally substituted 5- to 10-membered heteroaryl group” includes Specifically, for example, a halogen atom, —CH 2 —OC ( ⁇ O) —R 5 (wherein R 5 is C 1 -C 4 alkyl group optionally having 1 to 3 C 1 -C 4 alkyl groups).
- 6 ⁇ C 10 aryl group e.g., 2,4-dimethylphenyl group
- a chlorine atom, 2,4-dimethylphenyl carboxymethyl group is preferred.
- the “optionally substituted C 6 -C 10 aryl group” is preferably a 4-chlorophenyl group or a 4- (2,4-dimethylphenylcarboxymethyl) phenyl group.
- the “optionally substituted 5- to 10-membered heteroaryl group” is preferably a 3-thienyl group.
- R 3 is a hydroxy group, the substitution position of R 3 is not limited as long as it is on the isoquinoline ring, but the 1-position of the isoquinoline ring is preferable.
- a compound represented by the formula (Netersil) (chemical name: ⁇ 4-[(2S) -3-amino-1- (isoquinolin-6-ylamino) -1-oxopropan-2-yl] phenyl ⁇ methyl 2,4- Dimethylbenzoate ([4-[(2S) -3-amino-1- (isoquinolin-6-ylamino) -1-oxopropan-2-yl] phenyl] methyl 2,4-dimethylbenzoate), international general name: netarsudil) or The salt or solvate thereof is more preferable, and the following formula (4):
- Monohydrochloride of the compound represented by the above formula (6) (chemical name: rac- (2R) -2- (dimethylamino) -N- (1-oxo-1,2-dihydroisoquinoline- 6-yl) -2- (thiophen-3-yl) acetamide monohydrochloride (rac- (2R) -2- (dimethylamino) -N- (1-oxo-1,2-dihydroisoquinolin-6-yl) -2 -(thiophen-3-yl) acetamide monohydrochloride) (hereinafter sometimes referred to as “velosil monohydrochloride” in the present specification) is particularly preferable.
- the compound represented by the general formula (1) or a salt thereof or a solvate thereof is known and can be produced by a known method. Specifically, for example, it can be produced with reference to the methods described in Patent Documents 1 to 3 and the method described in Non-Patent Document 2. The contents of these documents are incorporated herein by reference. Moreover, the compound represented by General formula (1), its salt, or those solvates are marketed, and these commercial products may be used.
- commercially available products include, for example, netarsudil dimesylate (compound represented by formula (4)) manufactured by Medchemexpress and Chemscene LLS, and netarsudil monohydrochloride manufactured by Shanghai biopharmaleader (formula Monohydrochloride of the compound represented by (3)), velosil (free form of the compound represented by formula (6)) manufactured by MedKoo biosciences, and the like.
- the content of the compound represented by the general formula (1) or a salt thereof or a solvate thereof in the aqueous composition is not particularly limited, and is appropriately determined according to the disease applied, the sex, age, symptoms, etc. of the patient.
- the compound represented by the general formula (1) is converted into a free form in an amount of 0.0001 to 5 w / v% with respect to the total volume of the aqueous composition. It is preferably contained, more preferably 0.001 to 3 w / v%, even more preferably 0.005 to 2 w / v%, and particularly preferably 0.01 to 1 w / v%. .
- netersil is converted into a free form with respect to the total volume of the aqueous composition to be 0.0001. It is preferably contained in an amount of ⁇ 1 w / v%, more preferably 0.001 to 0.5 w / v%, further preferably 0.005 to 0.1 w / v%, more preferably 0.01 to 0 It is particularly preferable to contain 0.04 w / v%.
- velosil when used as the compound represented by the general formula (1), from the viewpoint of obtaining an excellent pharmacological action, velosil is converted to a free form with respect to the total volume of the aqueous composition to 0.01. Is preferably contained in an amount of about 3.5 to 3.5 w / v%, more preferably 0.1 to 2.5 w / v%, still more preferably 0.2 to 1.5 w / v%, It is particularly preferred to contain ⁇ 0.8 w / v%.
- the formula (8) Is preferably contained in a free form in an amount of 0.0001 to 3 w / v%, more preferably 0.001 to 2 w / v%, and more preferably 0.005 to 1 w / v%. It is more preferably contained, and particularly preferably 0.01 to 0.5 w / v%.
- the aqueous composition used in the present invention contains at least one selected from the group consisting of (B) acids, quaternary ammonium surfactants, polyhydric alcohols, and prostaglandins. Is included.
- (B) acids quaternary ammonium surfactants
- polyhydric alcohols polyhydric alcohols
- prostaglandins prostaglandins.
- Test Examples 1 to 6 when the aqueous composition containing the component (A) is contained in a polyolefin resin container, it is caused by adsorption to the resin due to storage under high temperature conditions. As a result, a decrease in the content of the compound represented by the general formula (1) may occur. Accordingly, it has been clarified that the content reduction is suppressed by further adding the component (B) to the aqueous composition.
- the “acids” are not particularly limited, and may be organic acids or inorganic acids.
- the “acids” one kind selected from the group consisting of “boric acids”, “phosphoric acids”, and “aliphatic carboxylic acids” from the viewpoint of suppressing a decrease in the content of the compound represented by the general formula (1) The above are preferable, and “boric acids” and “aliphatic carboxylic acids” are particularly preferable.
- boric acid refers to boric acid and salts thereof (for example, alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt; ammonium salt and the like) and solvates thereof. Means one or more selected from the group consisting of substances (hydrates, etc.). Specific examples of the boric acids include boric acid, ammonium borate, and borax. In the present specification, the “boric acid” is preferably at least one selected from the group consisting of boric acid and salts thereof, and boric acid is particularly preferable. These boric acids are all known and may be produced by a known method, or commercially available products may be used.
- phosphoric acids refers to phosphoric acid and salts thereof (for example, alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts; ammonium salts) and solvates thereof. Means one or more selected from the group consisting of substances (hydrates, etc.). Specific examples of such phosphoric acids include, for example, the following components listed in the Pharmaceutical Additives Dictionary 2016 (published by Yakuji Nippo Co., Ltd.): phosphoric acid, calcium monohydrogen phosphate, sodium monohydrogen phosphate.
- phosphoric acid sodium hydrogen phosphate hydrate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, diphosphate diphosphoric acid are used from the viewpoint of suppressing a decrease in the content of the compound represented by the general formula (1).
- One or more selected from the group consisting of sodium hydrogen hydrate, crystalline sodium dihydrogen phosphate, anhydrous sodium monohydrogen phosphate and anhydrous sodium dihydrogen phosphate are preferred.
- all of these phosphoric acids are well-known, may be manufactured by a well-known method, and may use a commercial item.
- aliphatic carboxylic acids refers to aliphatic carboxylic acids and salts thereof (for example, alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; ammonium salt) Etc.) and their solvates (hydrates, etc.).
- the number of carbon atoms in the aliphatic carboxylic acid is not particularly limited, but is preferably 2 to 20, more preferably 4 to 18, from the viewpoint of suppressing a decrease in the content of the compound represented by the general formula (1). 6 to 16 are particularly preferred.
- the carbon chain may be linear or branched, saturated or unsaturated, and a tertiary amino group or the like between the carbon and carbon atoms. You may have.
- the number of carboxyl groups in the aliphatic carboxylic acid is not particularly limited, but is preferably 1 to 4 and particularly preferably 2 to 4 from the viewpoint of suppressing a decrease in the content of the compound represented by the general formula (1).
- the “aliphatic carboxylic acids” may be a carboxylic acid (amino acid) having an amino group as a substituent and a carboxylic acid (oxycarboxylic acid) having a hydroxy group as a substituent.
- the number of substituents is not particularly limited, but is preferably 1 to 3 from the viewpoint of suppressing a decrease in the content of the compound represented by the general formula (1). Is particularly preferred.
- aliphatic carboxylic acids include aspartic acid such as sodium L-aspartate, potassium L-aspartate, magnesium L-aspartate or a salt thereof or a solvate thereof; DL-alanine Alanine such as L-alanine or a salt thereof or a solvate thereof; arginine or a salt thereof such as L-arginine or L-arginine hydrochloride or a solvate thereof; epsilon-aminocaproic acid; disodium calcium edetate; Edetic acid sodium hydrate, edetic acid tetrasodium or the like, or a salt thereof, or a solvate thereof; calcium citrate, citric acid hydrate, sodium citrate hydrate (trisodium citrate dihydrate) ), Sodium dihydrogen citrate, disodium citrate, none Citric acid such as citric acid and anhydrous sodium citrate or a salt thereof or a solvate thereof; glycine or a salt
- an aliphatic carboxylic acid having 2 to 4 carboxyl groups or a salt thereof or a solvate thereof is preferable, and edetic acid, citric acid, tartaric acid or a salt thereof or a solvate thereof is particularly preferable.
- all of these aliphatic carboxylic acids are publicly known, and may be manufactured by a publicly known method, and a commercial item may be used.
- the content of the acids in the aqueous composition is not particularly limited, and may be determined by appropriate examination. From the viewpoint of suppressing a decrease in the content of the compound represented by the general formula (1), the total amount of the aqueous composition is set. On the other hand, the content is preferably 0.0001 to 4 w / v%, more preferably 0.001 to 3 w / v%, and particularly preferably 0.002 to 2.5 w / v%. In particular, when boric acids are used as the acids, the content of the boric acids is not particularly limited and may be appropriately determined and determined, but the decrease in the content of the compound represented by the general formula (1) is suppressed.
- the content is preferably 0.003 to 2 w / v%, more preferably 0.01 to 1 w / v%, and more preferably 0.03 to 0.5 w / v based on the total volume of the aqueous composition.
- % Content is particularly preferable.
- the content of the aliphatic carboxylic acids is not particularly limited and may be determined by appropriate examination, but the content of the compound represented by the general formula (1) From the viewpoint of suppressing the decrease, it is preferably contained in an amount of 0.0001 to 3.5 w / v%, more preferably 0.005 to 2.5 w / v%, based on the total volume of the aqueous composition. It is particularly preferable to contain 0.01 to 1 w / v%.
- the content mass ratio of the compound represented by the general formula (1) or the salt thereof or the solvate thereof and the acids in the aqueous composition is not particularly limited, but the content of the compound represented by the general formula (1) is reduced. From the viewpoint of suppression, it is preferable to contain 0.0003 to 200 parts by mass of acids per 1 part by mass of the compound represented by the general formula (1) or a salt thereof or a solvate thereof as a free form.
- the content is more preferably 0.003 to 80 parts by mass, and particularly preferably 0.02 to 30 parts by mass.
- the content ratio of the boric acids is not particularly limited, but from the viewpoint of suppressing the decrease in the content of the compound represented by the general formula (1), the general formula (1) It is preferable to contain 0.0005 to 150 parts by mass, preferably 0.005 to 75 parts by mass of boric acid per 1 part by mass of the compound represented by the formula or a salt thereof or a solvate thereof.
- the content is more preferably 0.03 to 25 parts by mass.
- the content ratio by mass of the aliphatic carboxylic acids is not particularly limited, but from the viewpoint of suppressing a decrease in the content of the compound represented by the general formula (1), It is preferable to contain 0.05 to 150 parts by mass of an aliphatic carboxylic acid with respect to 1 part by mass of the compound represented by (1) or a salt thereof or a solvate thereof as a free form. More preferably, it is contained in an amount of 0.3 to 75 parts by mass.
- netarsudil is used as the compound represented by the general formula (1) and boric acids are used as the acids
- netarsudil or a salt thereof or a solvate thereof is used from the viewpoint of suppressing a decrease in the content of netarsudil.
- the free body preferably contains 0.5 to 100 parts by weight of boric acid, more preferably 1 to 50 parts by weight, and particularly preferably 2 to 20 parts by weight per 1 part by weight.
- velosil is used as the compound represented by the general formula (1) and boric acids are used as the acids
- velosil or a salt thereof or a solvate thereof is used from the viewpoint of suppressing a decrease in the content of velosil.
- boric acid is contained with respect to 1 part by mass as a free body, more preferably 0.01 to 1 part by mass, and 0.05 to 0.5 parts by mass. Is particularly preferred.
- the compound represented by the formula (8) is used as the compound represented by the general formula (1) and the boric acids are used as the acids, the content of the compound represented by the formula (8) is reduced. From the viewpoint of suppression, it is preferable to contain 0.01 to 80 parts by mass of boric acid per 1 part by mass of the compound represented by the formula (8) or a salt thereof or a solvate thereof as a free form. The content is more preferably 0.05 to 40 parts by mass, and particularly preferably 0.1 to 20 parts by mass.
- netarsudil is used as the compound represented by the general formula (1) and aliphatic carboxylic acids are used as the acids
- netarsudil or a salt thereof or a solvation thereof is used from the viewpoint of suppressing a decrease in the content of netarsudil.
- velosil in the case where velosil is used as the compound represented by the general formula (1) and aliphatic carboxylic acids are used as the acids, velosil or a salt thereof or a solvation thereof is used from the viewpoint of suppressing a decrease in the content of velosil. It is preferable to contain 0.01 to 30 parts by weight, more preferably 0.03 to 20 parts by weight, and more preferably 0.5 to 10 parts by weight of the aliphatic carboxylic acid relative to 1 part by weight of the product as a free form It is particularly preferable to contain it.
- the content of the compound represented by the formula (8) From the viewpoint of suppressing the decrease, 0.1 to 180 parts by mass of an aliphatic carboxylic acid is contained per 1 part by mass of the compound represented by the formula (8) or a salt thereof or a solvate thereof as a free form.
- the content is preferably 1 to 130 parts by mass, more preferably 3 to 80 parts by mass.
- examples of the “quaternary ammonium type surfactant” include benzalkonium chloride, benzethonium chloride, and benzododecinium bromide known as preservatives, and one of these is used alone. It may be used in combination of two or more.
- benzalkonium chloride and benzododecinium bromide are preferable from the viewpoint of suppressing a decrease in the content of the compound represented by the general formula (1). Particularly preferred.
- the quaternary ammonium type surfactant is known and may be produced by a known method, or a commercially available product may be used.
- the content of the quaternary ammonium type surfactant in the aqueous composition is not particularly limited and may be determined by appropriate examination, but from the viewpoint of suppressing a decrease in the content of the compound represented by the general formula (1).
- the total volume of the aqueous composition is preferably 0.00005 to 0.3 w / v%, more preferably 0.00025 to 0.2 w / v%, and 0.00025 to 0.15 w. / V% is particularly preferable.
- the content is preferably 0.0001 to 0.3 w / v%, more preferably 0.0005 to 0.2 w / v%, and particularly preferably 0.0005 to 0.15 w / v%.
- the content is preferably 0.0001 to 0.15 w / v%, more preferably 0.0005 to 0.05 w / v%, and particularly preferably 0.0005 to 0.02 w / v%.
- the content mass ratio of the compound represented by the general formula (1) or a salt thereof or a solvate thereof and the quaternary ammonium type surfactant in the aqueous composition is not particularly limited, but is represented by the general formula (1). From the viewpoint of suppressing a decrease in the content of the compound, a quaternary ammonium type surfactant is added to 1 part by mass of the compound represented by the general formula (1) or a salt thereof or a solvate thereof as a free form.
- the content is preferably 0.0005 to 8 parts by mass, more preferably 0.005 to 7 parts by mass, and particularly preferably 0.007 to 6 parts by mass.
- netarsudil is used as the compound represented by the general formula (1) and benzalkonium chloride is used as the quaternary ammonium type surfactant
- netarsudil is used from the viewpoint of suppressing a decrease in the content of netarthil.
- the content is preferably 0.5 to 3 parts by mass.
- velosil is used as the compound represented by the general formula (1) and benzalkonium chloride is used as the quaternary ammonium type surfactant
- velosil is used from the viewpoint of suppressing a decrease in the content of velosil.
- the compound represented by the formula (8) when used as the compound represented by the general formula (1) and benzalkonium chloride is used as the quaternary ammonium type surfactant, the compound represented by the formula (8) From the viewpoint of suppressing a decrease in the content of the compound represented by), 1 part by mass of the compound represented by the formula (8) or a salt thereof or a solvate thereof as a free form is reduced to 0. 0.05 to 5 parts by mass is preferable, 0.1 to 4 parts by mass is more preferable, and 0.5 to 3 parts by mass is particularly preferable.
- netarsudil is used as the compound represented by the general formula (1) and benzododecinium bromide is used as the quaternary ammonium type surfactant
- netarsudil is used from the viewpoint of suppressing a decrease in the content of netarthil.
- the content is preferably 0.6 to 3 parts by mass.
- velosil is used as the compound represented by the general formula (1) and benzododecinium bromide is used as the quaternary ammonium type surfactant
- velosil is used from the viewpoint of suppressing a decrease in the content of velosil.
- the compound represented by the formula (8) is used as the compound represented by the general formula (1) and the benzododecinium bromide is used as the quaternary ammonium type surfactant, the compound represented by the formula (8) From the viewpoint of suppressing a decrease in the content of the compound represented by), the amount of benzododecinium bromide is 0 with respect to 1 part by mass of the compound represented by formula (8) or a salt thereof or a solvate thereof as a free form. 0.07 to 5 parts by mass is preferable, 0.2 to 4 parts by mass is more preferable, and 0.4 to 3 parts by mass is particularly preferable.
- the “polyhydric alcohol” means an alcohol having two or more hydroxy groups in the same molecule, such as glycerin; sugars such as fructose and glucose; sugar alcohols such as sorbitol, mannitol, and xylitol; Trometamol; propylene glycol; macrogol 100, macrogol 200, macrogol 300, macrogol 400, macrogol 600, macrogol 1000, macrogol 1500, macrogol 1540, macrogol 4000, macrogol 6000, macrogol 20000, macro Examples include macrogol (polyethylene glycol) such as goal 35000, and one of these may be used alone, or two or more may be used in combination.
- macrogol polyethylene glycol
- glycerin, sorbitol, propylene glycol, mannitol, macrogol in particular, a decrease in the content of the compound represented by the general formula (1) from the viewpoint of suppressing the decrease in the content of the compound represented by the general formula (1).
- the average molecular weight is preferably from 100 to 10000, more preferably from 200 to 8000.
- the average molecular weight of Macrogol is the 17th revised Japanese Pharmacopoeia Pharmaceuticals Articles “Macrogol 400”.
- the average molecular weight test described in the item (1) is preferable, and D-mannitol, Macrogol 400, Macrogol 4000, and Macrogol 6000 are particularly preferable.
- polyhydric alcohol is well-known and may be manufactured by a well-known method, and a commercial item may be used.
- the content of the polyhydric alcohol in the aqueous composition is not particularly limited and may be determined by appropriate examination. From the viewpoint of suppressing the decrease in the content of the compound represented by the general formula (1), the entire aqueous composition The content is preferably 0.01 to 30 w / v%, more preferably 0.1 to 20 w / v%, and particularly preferably 0.5 to 5 w / v%. In particular, when mannitol is used as the polyhydric alcohol, mannitol is used in an amount of 0.1 to 25 w / v with respect to the total volume of the aqueous composition from the viewpoint of suppressing a decrease in the content of the compound represented by the general formula (1).
- the macrogol is 0.01 to 20 w relative to the total volume of the aqueous composition.
- / V% is preferable, 0.5 to 7 w / v% is more preferable, and 1 to 3 w / v% is particularly preferable.
- the content ratio of the compound represented by the general formula (1) or a salt thereof or a solvate thereof and the polyhydric alcohol in the aqueous composition is not particularly limited, but the content of the compound represented by the general formula (1) From the viewpoint of suppressing the decrease, 0.01 to 2500 parts by mass of polyhydric alcohol is contained per 1 part by mass of the compound represented by the general formula (1) or a salt thereof or a solvate thereof as a free form.
- the content is preferably 0.05 to 1500 parts by mass, more preferably 0.5 to 750 parts by mass.
- netarsudil is used as the compound represented by the general formula (1) and mannitol is used as the polyhydric alcohol
- netarsudil or a salt thereof or a solvate thereof is used from the viewpoint of suppressing a decrease in the content of netarsudil.
- velosil is used as the compound represented by the general formula (1) and mannitol is used as the polyhydric alcohol
- velosil or a salt thereof or a solvate thereof is used from the viewpoint of suppressing a decrease in the content of velosil.
- the compound represented by the formula (8) is used as the compound represented by the general formula (1) and mannitol is used as the polyhydric alcohol, the content of the compound represented by the formula (8) is decreased. From the viewpoint of suppressing the above, it is preferable to contain 10 to 2000 parts by mass of mannitol with respect to 1 part by mass of the compound represented by the formula (8) or a salt thereof or a solvate thereof as a free form. More preferably, it is contained in an amount of 30 to 500 parts by mass.
- netarsudil in the case where netarsudil is used as the compound represented by the general formula (1) and macrogol is used as the polyhydric alcohol, netarsudil or a salt thereof or a solvation thereof is used from the viewpoint of suppressing a decrease in the content of netarsudil. It is preferable to contain 10 to 900 parts by weight of macrogol, more preferably 30 to 600 parts by weight, and particularly preferably 50 to 300 parts by weight with respect to 1 part by weight of the product as a free body.
- velosil as the compound represented by the general formula (1) and using macrogol as the polyhydric alcohol
- velosil or a salt thereof or a solvation thereof is used from the viewpoint of suppressing a decrease in the content of velosil.
- the macrogol is preferably contained in an amount of 0.1 to 40 parts by weight, more preferably 0.5 to 30 parts by weight, and more preferably 1 to 20 parts by weight with respect to 1 part by weight of the product as a free body. Particularly preferred.
- the content of the compound represented by the formula (8) From the viewpoint of suppressing the decrease, it is preferable to contain 10 to 900 parts by mass of macrogol with respect to 1 part by mass of the compound represented by formula (8) or a salt thereof or a solvate thereof as a free form, More preferably, it is contained in an amount of ⁇ 600 parts by mass, particularly preferably 50-300 parts by mass.
- prostaglandins refers to prostaglandins, derivatives thereof and salts thereof (for example, alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt; ammonium salt) Etc.) and their solvates (hydrates, etc.).
- isopropyl unoprostone (chemical name: (+)-isopropyl (Z)- 7-[(1R, 2R, 3R, 5S) -3,5-dihydroxy-2- (3-oxodecyl) cyclopentyl] hept-5-enoate), Tafluprost (chemical name: 1-Methylethyl (5Z) -7- [ (1R, 2R, 3R, 5S) -2-[(1E) -3,3-difluoro-4-phenoxy-1-butenyl] -3,5-dihydroxycyclopentyl] -5-heptenoate), travoprost (chemical name: Isopropyl (5Z) -7-((1R, 2R, 3R, 5S) -3,5-dihydroxy-2-[(1E, 3R) -3-hydroxy-4- [3- (trifluoromethyl) phenoxy] but-1 -enyl] cycl
- the prostaglandins are selected from the group consisting of tafluprost, travoprost, bimatoprost, latanoprost and their salts, and their solvates from the viewpoint of suppressing a decrease in the content of the compound represented by the general formula (1).
- One or more are preferred, and latanoprost is particularly preferred.
- These prostaglandins are all known and may be produced by a known method, or commercially available products may be used.
- the content of the prostaglandins in the aqueous composition is not particularly limited and may be determined by appropriate examination. From the viewpoint of suppressing a decrease in the content of the compound represented by the general formula (1), the aqueous composition It is preferable to contain 0.00005 to 3 w / v% as a free body, more preferably 0.00025 to 0.25 w / v%, more preferably 0.00075 to 0.075 w / v% based on the total capacity. It is particularly preferable to contain it.
- the total volume of the aqueous composition is preferably contained in an amount of 0.0001 to 0.1 w / v%, more preferably 0.0005 to 0.05 w / v%, and more preferably 0.001 to 0.01 w / v%. It is particularly preferable to do this.
- the total volume of the aqueous composition The free form of tafluprost is preferably contained in an amount of 0.0001 to 0.02 w / v%, more preferably 0.0005 to 0.01 w / v%, and more preferably 0.001 to 0.005 w / v%. It is particularly preferable to do this.
- travoprost or a salt thereof or a solvate thereof as prostaglandins, from the viewpoint of suppressing a decrease in the content of the compound represented by the general formula (1),
- the total volume of the aqueous composition is preferably contained in an amount of 0.001 to 2 w / v%, more preferably 0.005 to 1 w / v%, and particularly preferably 0.01 to 0.5 w / v%. preferable.
- the content mass ratio of the compound represented by the general formula (1) or a salt thereof or a solvate thereof and the prostaglandins in the aqueous composition is not particularly limited, but the compound represented by the general formula (1) From the viewpoint of suppressing the decrease in the content, the compound represented by the general formula (1) or a salt thereof or a solvate thereof is used as 1 part by mass as a free form and 0.0001 to 50 as prostaglandins as a free form. It is preferably contained in an amount of 0.0125 to 12.5 parts by mass, particularly preferably 0.0375 to 3.75 parts by mass.
- netassil as the compound represented by the general formula (1) and using latanoprost or a salt thereof or a solvate thereof as the prostaglandins
- latanoprost or a salt thereof or a solvate thereof as the prostaglandins
- netarsudil as a compound represented by the general formula (1) and using tafluprost or a salt thereof or a solvate thereof as prostaglandins
- netarsudil as the compound represented by the general formula (1) and using travoprost or a salt thereof or a solvate thereof as the prostaglandins, from the viewpoint of suppressing a decrease in the content of netarsudil.
- netersudil as the compound represented by the general formula (1) and using bimatoprost or a salt thereof or a solvate thereof as the prostaglandins
- velosil as the compound represented by the general formula (1) and using latanoprost or a salt thereof or a solvate thereof as the prostaglandins
- the content is preferably 0.005 to 0.2 parts by mass.
- velosil as the compound represented by the general formula (1) and using tafluprost or a salt thereof or a solvate thereof as the prostaglandins, from the viewpoint of suppressing a decrease in the content of velosil, It is preferable to contain 0.0005 to 3 parts by mass of tafluprost as a free form, and 0.001 to 0.2 parts by mass of velosil or a salt thereof or a solvate thereof as a free form. Is more preferable, and it is particularly preferable to contain 0.002 to 0.1 parts by mass.
- Velosil or a salt thereof or a solvate thereof is preferably contained in an amount of 0.0003 to 0.2 parts by mass of travoprost as a free form, and 0.001 to 0.1 parts by mass of free form. More preferably, it is contained in an amount of 0.005 to 0.05 parts by mass.
- velosil as the compound represented by the general formula (1) and using bimatoprost or a salt thereof or a solvate thereof as the prostaglandins
- the content is preferably 0.1 to 2 parts by mass.
- the compound represented by the formula ( 8) is used as the compound represented by the general formula (1) and latanoprost or a salt thereof or a solvate thereof is used as the prostaglandins, the compound represented by the formula ( 8) From the viewpoint of suppressing a decrease in the content of the compound represented by 8), 1 part by mass of the compound represented by the formula (8) or a salt thereof or a solvate thereof as a free form and 0 as a free form of latanoprost
- the content is preferably 0.005 to 5 parts by mass, more preferably 0.025 to 2.5 parts by mass, and particularly preferably 0.05 to 0.5 parts by mass.
- the formula ( 8) From the viewpoint of suppressing the decrease in the content of the compound represented by formula (8), the compound represented by the formula (8) or a salt thereof or a solvate thereof is used as a free form with respect to 1 part by mass, and tafluprost is used as a free form.
- the content is preferably 0.005 to 1 part by mass, more preferably 0.025 to 0.5 part by mass, and particularly preferably 0.05 to 0.25 part by mass.
- the compound represented by the formula (8) is used as the compound represented by the general formula (1) and travoprost or a salt thereof or a solvate thereof is used as the prostaglandins
- the content is preferably 0.005 to 2.5 parts by mass, more preferably 0.025 to 0.5 parts by mass, and particularly preferably 0.05 to 0.25 parts by mass.
- the compound represented by the formula (8) is used as the compound represented by the general formula (1) and bimatoprost or a salt thereof or a solvate thereof is used as the prostaglandins
- the compound represented by the formula ( From the viewpoint of suppressing the decrease in the content of the compound represented by 8), 1 part by mass of the compound represented by the formula (8) or a salt thereof or a solvate thereof as 1 part by mass and 1 part by weight of bimatoprost as a free form
- the content is preferably 30 to 30 parts by mass, more preferably 5 to 25 parts by mass, and particularly preferably 10 to 20 parts by mass.
- the “aqueous composition” means a composition containing at least water, and its properties are not particularly limited as long as it can be accommodated in a container described later. Or suspension) and semi-solid (ointment).
- water in a composition purified water, water for injection, sterilized purified water, etc. can be used, for example.
- the content of water contained in the aqueous composition is not particularly limited, but is preferably 5% by mass or more, more preferably 20% by mass or more, further preferably 50% by mass or more, still more preferably 90% by mass or more, and more preferably 90 to 99.99 mass% is particularly preferable.
- the aqueous composition may contain additives used in pharmaceuticals, quasi drugs, etc., depending on the dosage form.
- additives include, for example, inorganic salts, isotonic agents, chelating agents, stabilizers, pH adjusters, preservatives, antioxidants, thickeners, surfactants, solubilizers, suspensions.
- examples include turbidizers, cooling agents, dispersants, preservatives, oily bases, emulsion bases, water-soluble bases, and the like.
- additives include sodium bisulfite, benzyl benzoate, fennel oil, ethanol, ethylene / vinyl acetate copolymer, potassium chloride, calcium chloride hydrate, sodium chloride, magnesium chloride, and alkyl hydrochloride.
- Diaminoethylglycine solution carboxyvinyl polymer, dry sodium sulfite, dry sodium carbonate, d-camphor, dl-camphor, creatinine, chlorobutanol, geraniol, sodium chondroitin sulfate, titanium oxide, dibutylhydroxytoluene, potassium bromide, sodium hydroxide , Polyoxyl stearate 45, purified lanolin, taurine, sodium bicarbonate, sodium carbonate hydrate, sodium thiosulfate hydrate, tyloxapol, sodium dehydroacetate, concentrated mixed toco Errol, white petrolatum, mint water, mint oil, ethyl paraoxybenzoate, butyl paraoxybenzoate, propyl paraoxybenzoate, methyl paraoxybenzoate, human serum albumin, sodium pyrosulfite, phenylethyl alcohol, bergamot oil, benzyl alcohol, povidone , Polyoxyethylene (200) poly
- potassium chloride potassium chloride, calcium chloride hydrate, sodium chloride, magnesium chloride, sodium hydroxide, sodium bicarbonate, sodium carbonate hydrate, povidone, polysorbate 80, polyoxyethylene hydrogenated castor oil, monostearin Preferred are acid polyethylene glycol, monoethanolamine, l-menthol and the like.
- the aqueous composition may further contain other medicinal ingredients depending on the disease to be applied.
- medicinal ingredients include ⁇ 1 receptor blockers including bunazosin such as bunazosin hydrochloride or a salt thereof or a solvate thereof; brimonidine or a salt thereof such as brimonidine tartrate or an solvate thereof; ⁇ 2 receptor agonist containing clonidine or a salt thereof or a solvate thereof; carteolol or a salt thereof such as carteolol hydrochloride or a solvate thereof, nipradilol or a salt thereof or a solvate thereof, timolol maleic acid Timolol such as a salt or a salt thereof, or a solvate thereof, betaxolol or a salt thereof such as betaxolol hydrochloride or a solvate thereof, levobanolol or a salt thereof such as levobanolol hydrochloride or a solvate thereof,
- the aqueous composition may not contain the prostaglandins. Good.
- examples of one embodiment of the aqueous composition used in the present invention include those other than the following ⁇ A-1> to ⁇ A-10>.
- ⁇ A-1> (rac) -2- (Dimethylamino) -N- (1-hydroxyisoquinolin-6-yl) -2- (thiophen-3-yl) acetamide hydrochloride, travoprost, boric acid, D- A composition comprising mannitol, benzalkonium chloride, polyoxyl 40 stearate, polyethylene glycol 400, EDTA, and purified water.
- ⁇ A-2> (rac) -2- (Dimethylamino) -N- (1-hydroxyisoquinolin-6-yl) -2- (thiophen-3-yl) acetamide hydrochloride, travoprost, boric acid, D- A composition comprising mannitol, benzalkonium chloride, Cremophor RH40, polyethylene glycol 400, EDTA, and purified water.
- ⁇ A-3> (rac) -2- (Dimethylamino) -N- (1-hydroxyisoquinolin-6-yl) -2- (thiophen-3-yl) acetamide hydrochloride, travoprost, boric acid, D- A composition comprising mannitol, polyoxyl 40 stearate, polyethylene glycol 400, EDTA, and purified water.
- ⁇ A-4> (rac) -2- (Dimethylamino) -N- (1-hydroxyisoquinolin-6-yl) -2- (thiophen-3-yl) acetamide hydrochloride, latanoprost, monobasic sodium phosphate , A composition comprising dibasic sodium phosphate, benzalkonium chloride, sodium chloride, EDTA, and purified water.
- ⁇ A-5> (rac) -2- (Dimethylamino) -N- (1-hydroxyisoquinolin-6-yl) -2- (thiophen-3-yl) acetamide hydrochloride, latanoprost, boric acid, D-mannitol , Benzalkonium chloride, EDTA, and purified water.
- ⁇ A-6> (rac) -2- (Dimethylamino) -N- (1-hydroxyisoquinolin-6-yl) -2- (thiophen-3-yl) acetamide hydrochloride, bimatoprost, monobasic sodium phosphate , A composition comprising dibasic sodium phosphate, benzalkonium chloride, sodium chloride, EDTA, and purified water.
- ⁇ A-7> (rac) -2- (Dimethylamino) -N- (1-hydroxyisoquinolin-6-yl) -2- (thiophen-3-yl) acetamide hydrochloride, bimatoprost, monobasic sodium phosphate , A composition comprising dibasic sodium phosphate, benzalkonium chloride, sodium chloride, EDTA, and purified water.
- ⁇ A-8> (rac) -2- (Dimethylamino) -N- (1-hydroxyisoquinolin-6-yl) -2- (thiophen-3-yl) acetamide hydrochloride, bimatoprost, boric acid, D-mannitol And a composition comprising purified water.
- the pH (25 ° C.) of the aqueous composition is not particularly limited, but is preferably 3 to 9, more preferably 3.5 to 8, further preferably 4 to 7, and particularly preferably 5 to 6.
- the osmotic pressure ratio with respect to physiological saline is not particularly limited, but is preferably 0.6 to 3, particularly preferably 0.6 to 2.
- the pharmaceutical preparation of the present invention uses a polyolefin resin container.
- the “container” means a package that directly contains the aqueous composition.
- Container is a concept encompassing any of “sealed container”, “airtight container”, and “sealed container” defined in the 17th revised Japanese Pharmacopoeia.
- the form of the container is not particularly limited as long as it can contain the aqueous composition, and may be appropriately selected and set according to the dosage form, the use of the pharmaceutical preparation, and the like.
- Specific examples of such a container include, for example, an injection container, an inhaler container, a spray container, a bottle container, a tube container, an eye drop container, a nasal drop container, Examples include ear container, bag container and the like.
- the container is preferably an eye drop container from the viewpoint of advantageously utilizing the pharmacological action of the compound represented by the general formula (1).
- the “polyolefin resin container” means a container in which at least a portion in contact with the aqueous composition is “polyolefin resin”. Therefore, for example, a container in which a polyolefin resin layer is provided on the inner layer in contact with the aqueous composition and a resin of another material is laminated on the outer side also corresponds to the “polyolefin resin container”.
- the polyolefin-based resin is not particularly limited, and may be a polymer (homopolymer) of a single type of monomer or a copolymer (copolymer) of a plurality of types of monomers.
- the polymerization mode is not particularly limited, and may be random polymerization or block polymerization. Furthermore, the stereoregularity (tacticity) is not particularly limited. Specific examples of such polyolefin resins include polyethylene (more specifically, for example, low density polyethylene (including linear low density polyethylene), high density polyethylene, medium density polyethylene, etc.), polypropylene, and cyclic polyolefin.
- a copolymer, an ethylene / ethyl acrylate copolymer, and the like can be mentioned, and one or more of these can be used in combination.
- polyethylene, polypropylene, and cyclic polyolefin are preferable, and polyethylene and polypropylene are more preferable from the viewpoint of suppressing a decrease in the content of the compound represented by the general formula (1) during high-temperature storage.
- “made of polyolefin resin” means that at least a part of the material contains a polyolefin resin, for example, two or more of a polyolefin resin and another resin.
- a resin mixture (polymer alloy) is also included in the “made of polyolefin resin”.
- the polyolefin resin container is preferably further kneaded with a substance that blocks the transmission of ultraviolet rays, such as an ultraviolet absorber and an ultraviolet scattering agent.
- a substance that blocks the transmission of ultraviolet rays such as an ultraviolet absorber and an ultraviolet scattering agent.
- the stability to light of the compound represented by the general formula (1) is improved.
- the ultraviolet light scattering agent include titanium oxide; zinc oxide and the like.
- ultraviolet absorbers examples include 2- (2H-benzotriazol-2-yl) -p-cresol (for example, Tinuvin P: BASF), 2- (2H-benzotriazol-2-yl) -4,6 -Bis (1-methyl-1-phenylethyl) phenol (eg Tinuvin 234: BASF), 2- (3,5-di-t-butyl-2-hydroxyphenyl) benzotriazole (eg Tinuvin320: BASF) ), 2- [5-chloro (2H) -benzotriazol-2-yl] -4-methyl-6- (tert-butyl) phenol (for example, Tinuvin 326: BASF), 2- (3,5-di -T-butyl-2-hydroxyphenyl) -5-chlorobenzotriazole (eg, Tinuvin327: BASF), 2- (2H-benzotriazol-2-yl) -4,6-di-tert Pentylphenol (for example, Tinu
- the blending ratio varies depending on the type of the substance, etc., for example, 0.001 to 50% by mass, preferably 0.002 to 25% in the container.
- the mass is preferably about 0.01 to 10 mass%, particularly preferably about 0.01 to 10 mass%.
- the interior of the polyolefin resin container is visible (observable) with the naked eye. If the inside is visible, there will be merits such that it is possible to inspect the presence or absence of foreign matter in the manufacturing process of the pharmaceutical preparation, and the user of the pharmaceutical preparation can check the remaining amount of the content (aqueous composition). .
- the visibility can be ensured at least on a part of the surface of the container (for example, even if the side surface of the eye drop container cannot be seen by a shrink film or the like, it can be visually recognized if the bottom surface is visible). It can be said.) If the inside is visible on a part of the surface of the container, this makes it possible to confirm the aqueous composition in the container.
- the means for accommodating the aqueous composition in the polyolefin resin container is not particularly limited, and may be filled by a conventional method according to the form of the container.
- compositions or aqueous compositions can be made into various dosage forms according to known methods described in, for example, the 17th revised Japanese Pharmacopoeia, General Rules for Preparations.
- the dosage form include injections, inhalation solutions, eye drops, eye ointments, ear drops, nasal solutions, enemas, external liquids, sprays, ointments, gels, oral solutions, syrups, etc. Is mentioned.
- an ophthalmic agent specifically an eye drop and an eye ointment are preferable, and an eye drop is particularly preferable. .
- the applicable disease of the pharmaceutical preparation is not particularly limited, and may be appropriately selected depending on the pharmacological action and the like of the compound represented by the general formula (1). Specifically, for example, it can be used as a preventive or therapeutic agent for ocular hypertension and glaucoma based on the Rho kinase inhibitory action, the norepinephrine transporter inhibitory action and the intraocular pressure reducing action of the compound represented by the general formula (1).
- glaucoma more specifically, for example, primary open-angle glaucoma, normal-tension glaucoma, excessive aqueous production glaucoma, acute closed-angle glaucoma, chronic closed-angle glaucoma, plateau iris syndrome, mixed glaucoma Steroid glaucoma, capsular glaucoma, pigment glaucoma, amyloid glaucoma, neovascular glaucoma, malignant glaucoma and the like.
- an aqueous composition or pharmaceutical preparation is used as a prophylactic or therapeutic agent for eye diseases (preferably diseases selected from ocular hypertension and glaucoma), for example, about 1 to 3 times a day, an appropriate amount May be administered.
- eye diseases preferably diseases selected from ocular hypertension and glaucoma
- R 1 and R 2 each independently represent a hydrogen atom or a C 1 -C 4 alkyl group
- R 3 represents a hydrogen atom or a hydroxy group
- A is —CH (R 4 ) — or —CH 2 —CH (R 4 ) —
- R 4 may have a C 6 -C 10 aryl group which may have a substituent, or may have a substituent).
- the tautomer is also contained in Formula (1).
- a method comprising a step of containing a seed or more and a step of accommodating the aqueous composition in a polyolefin resin container.
- the aqueous composition contains one or more selected from the group consisting of acids, quaternary ammonium surfactants, polyhydric alcohols, and prostaglandins, There is no question before and after the step of housing the aqueous composition in a polyolefin resin container.
- the method according to [10], wherein the compound represented by the general formula (1) is a compound represented by the formula (3) or (6).
- the compound represented by the general formula (1) is a compound represented by the formula (4) or (7).
- polyhydric alcohol is one or more selected from the group consisting of glycerin, sorbitol, propylene glycol, mannitol and macrogol.
- the prostaglandins are one or more selected from the group consisting of tafluprost, travoprost, bimatoprost, latanoprost and salts thereof, and solvates thereof, any of [10] to [17] the method of.
- Adsorption suppression test 1 Aqueous composition after storage for a certain period of time with a polyolefin resin section coexisting with an aqueous composition containing netassil for the purpose of examining the presence or absence of adsorption of netassil on a polyolefin resin container and the means for suppressing adsorption The presence or absence of a decrease in the content of netasil in the product was confirmed. That is, after preparing various aqueous compositions shown in Table 1 by a conventional method, 5 mL of them was placed in a glass container, and further, three pieces of polypropylene (PP) resin slices (each 1 cm ⁇ 2 cm) were added to the aqueous composition.
- PP polypropylene
- Example 1 The pharmaceutical preparation of Example 1 or Example 2 was obtained.
- a pharmaceutical preparation of Example 3 was obtained in the same manner as in Example 2 except that a polypropylene resin slice was not immersed.
- Each obtained pharmaceutical preparation was stored at 60 ° C. for 1 week.
- the concentration of netersudil in the aqueous composition before and after storage in each pharmaceutical preparation was measured.
- the concentration of netersudil in the aqueous composition was calculated by measuring the ratio of the peak area in the aqueous composition to the peak area of the netarsudil solution having a known concentration using HPLC. And from the density
- Residual rate (%) ⁇ (concentration of netarsudil in aqueous composition after storage) / (concentration of netarsudil in aqueous composition before storage) ⁇ ⁇ 100 The results are shown in Table 1.
- Example 2 From the comparison between Example 2 and Example 3, as shown in Table 1, the content of netarsudil in the aqueous composition when stored under high temperature conditions was further reduced by immersion of the resin section made of polypropylene. Such a decrease in the content was attributed to the immersion of polypropylene resin slices, and it was therefore presumed to be due to the adsorption of netassil to the polypropylene resin slices. However, from the comparison between Example 1 and Example 2, it was clarified that the decrease in the content of Netersudil is suppressed by further adding boric acid to the aqueous composition containing Netassil.
- an acid such as boric acid represented by boric acid is further added to an aqueous composition containing the compound represented by the general formula (1) represented by Netersudil or a salt thereof or a solvate thereof. It has been clarified that the content reduction (adsorption) that can occur when the material is contained in a polyolefin resin container typified by polypropylene and stored under high temperature conditions is relatively suppressed.
- Test Example 2 Adsorption suppression test 2 The test was carried out in the same manner as in Test Example 1, except that the formulation of the aqueous composition was changed as shown in Table 2. The results are shown in Table 2.
- Example 4 From the comparison between Example 4 and Example 5, as shown in Table 2, the decrease in the content of Netersil was also suppressed by adding sodium edetate hydrate to the aqueous composition containing Netersil.
- fats represented by edetate sodium hydrate are further added to an aqueous composition containing a compound represented by the general formula (1) represented by Netersudil or a salt thereof or a solvate thereof.
- a compound represented by the general formula (1) represented by Netersudil or a salt thereof or a solvate thereof By containing an acid such as an aromatic carboxylic acid, content reduction (adsorption) that can occur when stored in a polyolefin resin container typified by polypropylene and stored under high temperature conditions is relatively suppressed. It became clear.
- Adsorption suppression test 3 The test was carried out in the same manner as in Test Example 1, except that the formulation of the aqueous composition was changed as shown in Table 3. The results are shown in Table 3.
- Example 7 From the comparison between Example 7 and Example 8, as shown in Table 3, the decrease in the content of Netersudil was also suppressed by further adding benzalkonium chloride to the aqueous composition containing Netersudil.
- an aqueous composition containing the compound represented by the general formula (1) represented by Netersudil or a salt thereof, or a solvate thereof, and a fourth represented by benzalkonium chloride.
- a quaternary ammonium type surfactant By containing a quaternary ammonium type surfactant, content reduction (adsorption) that can occur when stored in a polyolefin resin container typified by polypropylene and stored under high temperature conditions is relatively suppressed. It became clear.
- Adsorption suppression test 4 The test was carried out in the same manner as in Test Example 1, except that the formulation of the aqueous composition was changed as shown in Table 4. The results are shown in Table 4.
- a polyhydric alcohol typified by D-mannitol was further added to an aqueous composition containing a compound represented by the general formula (1) typified by Netersudil or a salt thereof or a solvate thereof. It has been clarified that the content reduction (adsorption) that can occur when the material is contained in a polyolefin resin container typified by polypropylene and stored under high-temperature conditions is relatively suppressed.
- Adsorption suppression test 5 The test was carried out in the same manner as in Test Example 1, except that the formulation of the aqueous composition was changed as shown in Table 5. The results are shown in Table 5.
- Example 13 From the comparison between Example 13 and Example 14, as shown in Table 5, the decrease in the content of Netersudil was also suppressed by further adding Macrogol 400 to the aqueous composition containing Netersudil.
- a polyhydric alcohol typified by Macrogol 400 is further added to an aqueous composition containing a compound represented by the general formula (1) typified by Netersudil or a salt thereof or a solvate thereof. It has been clarified that the content reduction (adsorption) that can occur when the material is contained in a polyolefin resin container typified by polypropylene and stored under high-temperature conditions is relatively suppressed.
- Adsorption suppression test 6 The test was carried out by the same method as in Test Example 1 except that the formulation of the aqueous composition was changed as shown in Table 6. The results are shown in Table 6.
- the aqueous composition containing the compound represented by the general formula (1) represented by Netersudil or a salt thereof or a solvate thereof further contains prostaglandins represented by latanoprost. It has been clarified that the content reduction (adsorption) that can occur when stored in a polyolefin resin container typified by polypropylene and stored under high temperature conditions is relatively suppressed.
- the concentration of netarsudil in the aqueous composition before and after storage in each pharmaceutical preparation was calculated by the same method as in Test Example 1. And from the density
- Residual rate (%) ⁇ (concentration of netarsudil in aqueous composition after storage) / (concentration of netarsudil in aqueous composition before storage) ⁇ ⁇ 100 The results are shown in Table 8.
- Production Examples 37 to 72 In Production Examples 1 to 36, the pharmaceutical preparations of Production Examples 37 to 72 can be produced using polypropylene eye drop containers instead of high density polyethylene.
- Production Examples 73 to 108 In Production Examples 1 to 36, the pharmaceutical preparations of Production Examples 73 to 108 can be produced using eye drops containers made of cyclic polyolefin instead of high density polyethylene.
- Production Examples 109 to 144 In Production Examples 1 to 36, the pharmaceutical preparations of Production Examples 109 to 144 can be produced using eye drop containers made of low density polyethylene instead of high density polyethylene.
- Production Examples 145 to 288 In Production Examples 1 to 144, 0.5 g of velosil monohydrochloride as a free form can be produced in the usual manner as the pharmaceutical preparations of Production Examples 145 to 288 instead of Netersudil dimesylate.
- Production Examples 289 to 432 In Production Examples 1 to 144, 0.7 g of velosidyl monohydrochloride as a free form can be produced in the usual manner as the pharmaceutical preparations of Production Examples 289 to 432 instead of Netersudil dimesylate.
- Production Examples 433 to 576 In Production Examples 1 to 144, 0.02 g of the compound represented by the formula (8) can be produced in the usual manner as the pharmaceutical preparations of Production Examples 433 to 576 instead of Netersudil dimesylate. .
- a pharmaceutical preparation excellent in stability can be provided and can be suitably used in the pharmaceutical industry and the like.
Abstract
Description
具体的には例えば、以下の構造式:
そのため、これらのイソキノリン-6-アミノ誘導体を、例えば眼科用剤等として安定的に製剤化する技術を確立することは、極めて有用である。
そこで、本発明者は、イソキノリン-6-アミノ誘導体の、水性組成物中での含量低下を抑制するため更に鋭意検討した。しかるところ、イソキノリン-6-アミノ誘導体を含有する水性組成物に、さらに酸類、第4級アンモニウム型界面活性剤、多価アルコール、及びプロスタグランジン類よりなる群から選ばれる1種以上の成分を含有せしめ、これをポリオレフィン系樹脂製容器に収容することにより、含量低下が抑制され、安定性の改善された医薬製剤となることを見出し、本発明を完成した。
(A)下記の一般式(1)
R3は水素原子又はヒドロキシ基を示し、
Aは-CH(R4)-又は-CH2-CH(R4)-(ここでR4は置換基を有してもよいC6~C10アリール基、又は置換基を有してもよい5~10員のヘテロアリール基を示す。)を示し、
さらに、式(1)には、その互変異性体も含まれる。)
で表される化合物若しくはその塩又はそれらの溶媒和物;
(B)酸類、第4級アンモニウム型界面活性剤、多価アルコール及びプロスタグランジン類よりなる群から選ばれる1種以上;
を含有する水性組成物が、ポリオレフィン系樹脂製容器に収容されてなる、医薬製剤を提供するものである。
本明細書において、「一般式(1)
R3は水素原子又はヒドロキシ基を示し、
Aは-CH(R4)-又は-CH2-CH(R4)-(ここでR4は置換基を有してもよいC6~C10アリール基、又は置換基を有してもよい5~10員のヘテロアリール基を示す。)を示し、
さらに、式(1)には、その互変異性体も含まれる。)
で表される化合物若しくはその塩又はそれらの溶媒和物」には、一般式(1)で表される化合物そのもののほか、その塩や溶媒和物も含まれる。
また、一般式(1)で表される化合物やその塩の溶媒和物としては、水和物やアルコール和物等が挙げられる。
さらに、一般式(1)で表される化合物の化学構造中に不斉炭素が存する場合には、種々の立体異性体が存在し得るが、一般式(1)で表される化合物としてはその立体配置は特に限定されず、単一の立体異性体でも、各種立体異性体の任意の割合の混合物でもよい。
なお、本明細書において、各種の式で表される化合物がその化学構造中に不斉炭素を有する場合においては、特に立体配置を指定しない限り、斯かる式は各種立体異性体単独及びそれらの任意の割合の混合物の全てを包含する。従って、特に立体配置を指定しない式で表される化合物は、単一の立体異性体であってもよく、また、各種立体異性体の任意の割合の混合物であってもよい。
本明細書において、「C6~C10アリール基」とは、炭素数6~10のアリール基を意味する。「C6~C10アリール基」としては、具体的には例えば、フェニル基、ナフチル基等が挙げられ、フェニル基が好ましい。
本明細書において、「置換基を有してもよいC6~C10アリール基」としては、4-クロロフェニル基、4-(2,4-ジメチルフェニルカルボキシメチル)フェニル基が好ましい。
本明細書において、「置換基を有してもよい5~10員のヘテロアリール基」としては、3-チエニル基が好ましい。
R3がヒドロキシ基である場合、R3の置換位置はイソキノリン環上であれば限定されないが、イソキノリン環の1位が好ましい。
また、別の態様として、「一般式(1)で表される化合物若しくはその塩又はそれらの溶媒和物」としては、下記式(5)又は(5'):
また、一般式(1)で表される化合物若しくはその塩又はそれらの溶媒和物は市販されており、これらの市販品を用いてもよい。市販品としては、具体的には例えば、Medchemexpress社製やChemscene LLS社製のネタースジル2メシル酸塩(式(4)で表される化合物)や、Shanghai biopharmaleader社製のネタースジルの1塩酸塩(式(3)で表される化合物の1塩酸塩)、MedKoo biosciences社製のヴェロスジル(式(6)で表される化合物のフリー体)などが挙げられる。
特に、一般式(1)で表される化合物としてネタースジルを使用する場合においては、優れた薬理作用を得る観点から、水性組成物全容量に対して、ネタースジルをフリー体に換算して0.0001~1w/v%含有するのが好ましく、0.001~0.5w/v%含有するのがより好ましく、0.005~0.1w/v%含有するのがさらに好ましく、0.01~0.04w/v%含有するのが特に好ましい。
また、一般式(1)で表される化合物としてヴェロスジルを使用する場合においては、優れた薬理作用を得る観点から、水性組成物全容量に対して、ヴェロスジルをフリー体に換算して0.01~3.5w/v%含有するのが好ましく、0.1~2.5w/v%含有するのがより好ましく、0.2~1.5w/v%含有するのがさらに好ましく、0.3~0.8w/v%含有するのが特に好ましい。
さらに、一般式(1)で表される化合物として式(8)で表される化合物を使用する場合においては、優れた薬理作用を得る観点から、水性組成物全容量に対して、式(8)で表される化合物をフリー体に換算して0.0001~3w/v%含有するのが好ましく、0.001~2w/v%含有するのがより好ましく、0.005~1w/v%含有するのがさらに好ましく、0.01~0.5w/v%含有するのが特に好ましい。
本発明で用いる水性組成物は、上記成分(A)に加えて、(B)酸類、第4級アンモニウム型界面活性剤、多価アルコール及びプロスタグランジン類よりなる群から選ばれる1種以上を含むものである。
後記試験例1~6に具体的に示される通り、成分(A)を含有する水性組成物をポリオレフィン系樹脂製容器に収容した場合、高温条件下での保存により、樹脂への吸着に起因すると推察される、一般式(1)で表される化合物の含量低下が生じ得る。しかるところ、水性組成物に、さらに成分(B)を含有せしめることにより、含量低下が抑制されることが明らかとなった。
ホウ酸類としては、具体的には例えば、ホウ酸、ホウ酸アンモニウム、ホウ砂等が挙げられる。本明細書において、「ホウ酸類」としては、ホウ酸及びその塩よりなる群から選ばれる1種以上が好ましく、ホウ酸が特に好ましい。
なお、これらのホウ酸類はいずれも公知であり、公知の方法により製造しても良く、市販品を使用しても良い。
このようなリン酸類としては、具体的には例えば、医薬品添加物辞典2016(株式会社薬事日報社発行)に収載の、以下の成分:リン酸、リン酸一水素カルシウム、リン酸一水素ナトリウム・七水和物、リン酸三ナトリウム、リン酸水素カルシウム水和物、リン酸水素カルシウム造粒物、リン酸水素ナトリウム水和物、リン酸水素ナトリウム七水和物、リン酸水素ナトリウム二水和物、リン酸水素二ナトリウム二水和物、リン酸二カリウム、リン酸二水素カリウム、リン酸二水素カルシウム水和物、リン酸二水素ナトリウム、リン酸二水素ナトリウム一水和物、結晶リン酸二水素ナトリウム、ピロリン酸カルシウム、ピロリン酸四ナトリウム、無水ピロリン酸ナトリウム、無水リン酸一水素ナトリウム、無水リン酸三ナトリウム、無水リン酸水素カルシウム、無水リン酸水素カルシウム造粒物、無水リン酸二水素ナトリウム、ポリリン酸カルシウム、ポリリン酸ナトリウム等が挙げられる。これらの中では、一般式(1)で表される化合物の含量低下を抑制する観点から、リン酸、リン酸水素ナトリウム水和物、リン酸二水素カリウム、リン酸二水素ナトリウム、リン酸二水素ナトリウム一水和物、結晶リン酸二水素ナトリウム、無水リン酸一水素ナトリウム及び無水リン酸二水素ナトリウムよりなる群から選ばれる1種以上が好ましい。
なお、これらのリン酸類はいずれも公知であり、公知の方法により製造しても良く、市販品を使用しても良い。また、リン酸類としては、他の成分と塩や錯体を形成したものを用いても良い。
なお、「脂肪族カルボン酸類」としては、置換基としてアミノ基を有するカルボン酸(アミノ酸)、置換基としてヒドロキシ基を有するカルボン酸(オキシカルボン酸)であっても良い。この場合、置換基の置換数は特に限定されないが、一般式(1)で表される化合物の含量低下を抑制する観点から、1~3個であるのが好ましく、1~2個であるのが特に好ましい。
なお、これらの脂肪族カルボン酸類はいずれも公知であり、公知の方法により製造しても良く、市販品を使用しても良い。また、脂肪族カルボン酸類としては、他の成分と塩や錯体を形成したものを使用しても良い。
また、一般式(1)で表される化合物としてヴェロスジルを使用し、酸類としてホウ酸類を使用する場合においては、ヴェロスジルの含量低下を抑制する観点から、ヴェロスジル若しくはその塩又はそれらの溶媒和物をフリー体として1質量部に対し、ホウ酸類を0.001~5質量部含有するのが好ましく、0.01~1質量部含有するのがより好ましく、0.05~0.5質量部含有するのが特に好ましい。
さらに、一般式(1)で表される化合物として式(8)で表される化合物を使用し、酸類としてホウ酸類を使用する場合においては、式(8)で表される化合物の含量低下を抑制する観点から、式(8)で表される化合物若しくはその塩又はそれらの溶媒和物をフリー体として1質量部に対し、ホウ酸類を0.01~80質量部含有するのが好ましく、0.05~40質量部含有するのがより好ましく、0.1~20質量部含有するのが特に好ましい。
また、一般式(1)で表される化合物としてヴェロスジルを使用し、酸類として脂肪族カルボン酸類を使用する場合においては、ヴェロスジルの含量低下を抑制する観点から、ヴェロスジル若しくはその塩又はそれらの溶媒和物をフリー体として1質量部に対し、脂肪族カルボン酸類を0.01~30質量部含有するのが好ましく、0.03~20質量部含有するのがより好ましく、0.5~10質量部含有するのが特に好ましい。
さらに、一般式(1)で表される化合物として式(8)で表される化合物を使用し、酸類として脂肪族カルボン酸類を使用する場合においては、式(8)で表される化合物の含量低下を抑制する観点から、式(8)で表される化合物若しくはその塩又はそれらの溶媒和物をフリー体として1質量部に対し、脂肪族カルボン酸類を0.1~180質量部含有するのが好ましく、1~130質量部含有するのがより好ましく、3~80質量部含有するのが特に好ましい。
なお、第4級アンモニウム型界面活性剤は公知であり、公知の方法により製造しても良く、市販品を用いても良い。
特に、一般式(1)で表される化合物としてネタースジルを使用し、第4級アンモニウム型界面活性剤としてベンザルコニウム塩化物を使用する場合においては、ネタースジルの含量低下を抑制する観点から、ネタースジル若しくはその塩又はそれらの溶媒和物をフリー体として1質量部に対し、ベンザルコニウム塩化物を0.05~5質量部含有するのが好ましく、0.1~4質量部含有するのがより好ましく、0.5~3質量部含有するのが特に好ましい。
また、一般式(1)で表される化合物としてヴェロスジルを使用し、第4級アンモニウム型界面活性剤としてベンザルコニウム塩化物を使用する場合においては、ヴェロスジルの含量低下を抑制する観点から、ヴェロスジル若しくはその塩又はそれらの溶媒和物をフリー体として1質量部に対し、ベンザルコニウム塩化物を0.001~1質量部含有するのが好ましく、0.005~0.5質量部含有するのがより好ましく、0.01~0.3質量部含有するのが特に好ましい。
また、一般式(1)で表される化合物として式(8)で表される化合物を使用し、第4級アンモニウム型界面活性剤としてベンザルコニウム塩化物を使用する場合においては、式(8)で表される化合物の含量低下を抑制する観点から、式(8)で表される化合物若しくはその塩又はそれらの溶媒和物をフリー体として1質量部に対し、ベンザルコニウム塩化物を0.05~5質量部含有するのが好ましく、0.1~4質量部含有するのがより好ましく、0.5~3質量部含有するのが特に好ましい。
また、一般式(1)で表される化合物としてヴェロスジルを使用し、第4級アンモニウム型界面活性剤としてベンゾドデシニウム臭化物を使用する場合においては、ヴェロスジルの含量低下を抑制する観点から、ヴェロスジル若しくはその塩又はそれらの溶媒和物をフリー体として1質量部に対し、ベンゾドデシニウム臭化物を0.003~0.8質量部含有するのが好ましく、0.007~0.4質量部含有するのがより好ましく、0.01~0.1質量部含有するのが特に好ましい。
さらに、一般式(1)で表される化合物として式(8)で表される化合物を使用し、第4級アンモニウム型界面活性剤としてベンゾドデシニウム臭化物を使用する場合においては、式(8)で表される化合物の含量低下を抑制する観点から、式(8)で表される化合物若しくはその塩又はそれらの溶媒和物をフリー体として1質量部に対し、ベンゾドデシニウム臭化物を0.07~5質量部含有するのが好ましく、0.2~4質量部含有するのがより好ましく、0.4~3質量部含有するのが特に好ましい。
なお、多価アルコールは公知であり、公知の方法により製造しても良いし、市販品を用いても良い。
特に、一般式(1)で表される化合物としてネタースジルを使用し、多価アルコールとしてマンニトールを使用する場合においては、ネタースジルの含量低下を抑制する観点から、ネタースジル若しくはその塩又はそれらの溶媒和物をフリー体として1質量部に対し、マンニトールを10~2000質量部含有するのが好ましく、20~1000質量部含有するのがより好ましく、30~500質量部含有するのが特に好ましい。
また、一般式(1)で表される化合物としてヴェロスジルを使用し、多価アルコールとしてマンニトールを使用する場合においては、ヴェロスジルの含量低下を抑制する観点から、ヴェロスジル若しくはその塩又はそれらの溶媒和物をフリー体として1質量部に対し、マンニトールを0.1~200質量部含有するのが好ましく、0.5~100質量部含有するのがより好ましく、1~50質量部含有するのが特に好ましい。
さらに、一般式(1)で表される化合物として式(8)で表される化合物を使用し、多価アルコールとしてマンニトールを使用する場合においては、式(8)で表される化合物の含量低下を抑制する観点から、式(8)で表される化合物若しくはその塩又はそれらの溶媒和物をフリー体として1質量部に対し、マンニトールを10~2000質量部含有するのが好ましく、20~1000質量部含有するのがより好ましく、30~500質量部含有するのが特に好ましい。
また、一般式(1)で表される化合物としてヴェロスジルを使用し、多価アルコールとしてマクロゴールを使用する場合においては、ヴェロスジルの含量低下を抑制する観点から、ヴェロスジル若しくはその塩又はそれらの溶媒和物をフリー体として1質量部に対し、マクロゴールを0.1~40質量部含有するのが好ましく、0.5~30質量部含有するのがより好ましく、1~20質量部含有するのが特に好ましい。
さらに、一般式(1)で表される化合物として式(8)で表される化合物を使用し、多価アルコールとしてマクロゴールを使用する場合においては、式(8)で表される化合物の含量低下を抑制する観点から、式(8)で表される化合物若しくはその塩又はそれらの溶媒和物をフリー体として1質量部に対し、マクロゴールを10~900質量部含有するのが好ましく、30~600質量部含有するのがより好ましく、50~300質量部含有するのが特に好ましい。
プロスタグランジン類としては、一般式(1)で表される化合物の含量低下を抑制する観点から、タフルプロスト、トラボプロスト、ビマトプロスト、ラタノプロスト及びそれらの塩並びにそれらの溶媒和物よりなる群から選ばれる1種以上が好ましく、ラタノプロストが特に好ましい。
なお、これらのプロスタグランジン類はいずれも公知であり、公知の方法により製造しても良く、市販品を使用しても良い。
特に、一般式(1)で表される化合物としてネタースジルを使用し、プロスタグランジン類としてラタノプロスト若しくはその塩又はそれらの溶媒和物を使用する場合においては、ネタースジルの含量低下を抑制する観点から、ネタースジル若しくはその塩又はそれらの溶媒和物をフリー体として1質量部に対し、ラタノプロストをフリー体として0.005~5質量部含有するのが好ましく、0.025~2.5質量部含有するのがより好ましく、0.05~0.5質量部含有するのが特に好ましい。また、一般式(1)で表される化合物としてネタースジルを使用し、プロスタグランジン類としてタフルプロスト若しくはその塩又はそれらの溶媒和物を使用する場合においては、ネタースジルの含量低下を抑制する観点から、ネタースジル若しくはその塩又はそれらの溶媒和物をフリー体として1質量部に対し、タフルプロストをフリー体として0.005~1質量部含有するのが好ましく、0.025~0.5質量部含有するのがより好ましく、0.05~0.25質量部含有するのが特に好ましい。また、一般式(1)で表される化合物としてネタースジルを使用し、プロスタグランジン類としてトラボプロスト若しくはその塩又はそれらの溶媒和物を使用する場合においては、ネタースジルの含量低下を抑制する観点から、ネタースジル若しくはその塩又はそれらの溶媒和物をフリー体として1質量部に対し、トラボプロストをフリー体として0.005~2.5質量部含有するのが好ましく、0.025~0.5質量部含有するのがより好ましく、0.05~0.25質量部含有するのが特に好ましい。さらに、一般式(1)で表される化合物としてネタースジルを使用し、プロスタグランジン類としてビマトプロスト若しくはその塩又はそれらの溶媒和物を使用する場合においては、ネタースジルの含量低下を抑制する観点から、ネタースジル若しくはその塩又はそれらの溶媒和物をフリー体として1質量部に対し、ビマトプロストをフリー体として1~30質量部含有するのが好ましく、5~25質量部含有するのがより好ましく、10~20質量部含有するのが特に好ましい。
水性組成物に含まれる水の含有量は特に限定されないが、5質量%以上が好ましく、20質量%以上がより好ましく、50質量%以上がさらに好ましく、90質量%以上がさらにより好ましく、90~99.99質量%が特に好ましい。
これら添加物の中では、塩化カリウム、塩化カルシウム水和物、塩化ナトリウム、塩化マグネシウム、水酸化ナトリウム、炭酸水素ナトリウム、炭酸ナトリウム水和物、ポビドン、ポリソルベート80、ポリオキシエチレン硬化ヒマシ油、モノステアリン酸ポリエチレングリコール、モノエタノールアミン、l-メントール等が好ましい。
他の薬効成分としては、β遮断薬が好ましく、チモロールが好ましい。
また、本発明で用いる水性組成物の一つの態様としては、例えば、以下の<A-1>~<A-10>以外のものが挙げられる。
<A-1> (rac)-2-(ジメチルアミノ)-N-(1-ヒドロキシイソキノリン-6-イル)-2-(チオフェン-3-イル)アセトアミド塩酸塩、トラボプロスト、ホウ酸、D-マンニトール、塩化ベンザルコニウム、ステアリン酸ポリオキシル40、ポリエチレングリコール400、EDTA、及び精製水を含む組成物。
<A-2> (rac)-2-(ジメチルアミノ)-N-(1-ヒドロキシイソキノリン-6-イル)-2-(チオフェン-3-イル)アセトアミド塩酸塩、トラボプロスト、ホウ酸、D-マンニトール、塩化ベンザルコニウム、クレモフォールRH40、ポリエチレングリコール400、EDTA、及び精製水を含む組成物。
<A-3> (rac)-2-(ジメチルアミノ)-N-(1-ヒドロキシイソキノリン-6-イル)-2-(チオフェン-3-イル)アセトアミド塩酸塩、トラボプロスト、ホウ酸、D-マンニトール、ステアリン酸ポリオキシル40、ポリエチレングリコール400、EDTA、及び精製水を含む組成物。
<A-4> (rac)-2-(ジメチルアミノ)-N-(1-ヒドロキシイソキノリン-6-イル)-2-(チオフェン-3-イル)アセトアミド塩酸塩、ラタノプロスト、一塩基性リン酸ナトリウム、二塩基性リン酸ナトリウム、塩化ベンザルコニウム、塩化ナトリウム、EDTA、及び精製水を含む組成物。
<A-5> (rac)-2-(ジメチルアミノ)-N-(1-ヒドロキシイソキノリン-6-イル)-2-(チオフェン-3-イル)アセトアミド塩酸塩、ラタノプロスト、ホウ酸、D-マンニトール、塩化ベンザルコニウム、EDTA、及び精製水を含む組成物。
<A-6> (rac)-2-(ジメチルアミノ)-N-(1-ヒドロキシイソキノリン-6-イル)-2-(チオフェン-3-イル)アセトアミド塩酸塩、ビマトプロスト、一塩基性リン酸ナトリウム、二塩基性リン酸ナトリウム、塩化ベンザルコニウム、塩化ナトリウム、EDTA、及び精製水を含む組成物。
<A-7> (rac)-2-(ジメチルアミノ)-N-(1-ヒドロキシイソキノリン-6-イル)-2-(チオフェン-3-イル)アセトアミド塩酸塩、ビマトプロスト、一塩基性リン酸ナトリウム、二塩基性リン酸ナトリウム、塩化ベンザルコニウム、塩化ナトリウム、EDTA、及び精製水を含む組成物。
<A-8> (rac)-2-(ジメチルアミノ)-N-(1-ヒドロキシイソキノリン-6-イル)-2-(チオフェン-3-イル)アセトアミド塩酸塩、ビマトプロスト、ホウ酸、D-マンニトール、及び精製水を含む組成物。
<A-9> 2,4-ジメチル安息香酸(S)-4-(3-アミノ-1-(イソキノリン-6-イルアミノ)-1-オキソプロパン-2-イル)ベンジル、トラボプロスト、ホウ酸、D-マンニトール、塩化ベンザルコニウム、ステアリン酸ポリオキシル40、ポリエチレングリコール400、EDTA、及び精製水を含む組成物。
<A-10> 2,4-ジメチル安息香酸(S)-4-(3-アミノ-1-(イソキノリン-6-イルアミノ)-1-オキソプロパン-2-イル)ベンジル、ラタノプロスト、ホウ酸、D-マンニトール、塩化ベンザルコニウム、ステアリン酸ポリオキシル40、ポリエチレングリコール400、EDTA、及び精製水を含む組成物。
本明細書において、「容器」とは、前記水性組成物を直接的に収容する包装体を意味する。容器は、第十七改正日本薬局方 通則に定義される「密閉容器」、「気密容器」、「密封容器」のいずれをも包含する概念である。
容器としては、一般式(1)で表される化合物の有する薬理作用を有利に利用する観点から、点眼剤用容器であるのが好ましい。
このようなポリオレフィン系樹脂としては、具体的には例えば、ポリエチレン(より詳細には例えば低密度ポリエチレン(直鎖状低密度ポリエチレンを含む)、高密度ポリエチレン、中密度ポリエチレンなど)、ポリプロピレン、環状ポリオレフィン、ポリ(4-メチルペンテン)、ポリテトラフルオロエチレン、エチレン・プロピレン共重合体、エチレン・α-オレフィン共重合体、エチレン・アクリル酸共重合体、エチレン・メタクリル酸共重合体、エチレン・酢酸ビニル共重合体、エチレン・アクリル酸エチル共重合体等が挙げられ、これらの1種又は2種以上を組み合わせて使用できる。ポリオレフィン系樹脂としては、一般式(1)で表される化合物の、高温保存時の含量低下を抑制する観点から、ポリエチレン、ポリプロピレン、環状ポリオレフィンが好ましく、ポリエチレン、ポリプロピレンがより好ましい。
なお、本明細書において、「ポリオレフィン系樹脂製」とは、その材質の少なくとも一部にポリオレフィン系樹脂を含んでいることを意味し、例えば、ポリオレフィン系樹脂と他の樹脂との2種以上の樹脂の混合体(ポリマーアロイ)も「ポリオレフィン系樹脂製」に含まれる。
具体的には例えば、一般式(1)で表される化合物の有するRhoキナーゼ阻害作用、ノルエピネフリントランスポーター阻害作用や眼圧低下作用に基づき、高眼圧症や緑内障の予防又は治療剤として利用できる。ここで、緑内障としては、より詳細には例えば、原発性開放隅角緑内障、正常眼圧緑内障、房水産生過多緑内障、急性閉塞隅角緑内障、慢性閉塞隅角緑内障、plateau iris syndrome、混合型緑内障、ステロイド緑内障、水晶体の嚢性緑内障、色素緑内障、アミロイド緑内障、血管新生緑内障、悪性緑内障などが挙げられる。
[1] 次の成分(A)及び(B):
(A)下記の一般式(1)
R3は水素原子又はヒドロキシ基を示し、
Aは-CH(R4)-又は-CH2-CH(R4)-(ここでR4は置換基を有してもよいC6~C10アリール基、又は置換基を有してもよい5~10員のヘテロアリール基を示す。)を示し、
さらに、式(1)には、その互変異性体も含まれる。)
で表される化合物若しくはその塩又はそれらの溶媒和物;
(B)酸類、第4級アンモニウム型界面活性剤、多価アルコール及びプロスタグランジン類よりなる群から選ばれる1種以上;
を含有する水性組成物が、ポリオレフィン系樹脂製容器に収容されてなる、医薬製剤。
[2] 前記一般式(1)で表される化合物が、下記式(2)、(5)、(5')又は(8):
[3] 前記一般式(1)で表される化合物が、下記式(3)又は(6):
[5] ポリオレフィン系樹脂が、ポリエチレン又はポリプロピレンである、[1]~[4]のいずれか記載の医薬製剤。
[6] 酸類が、ホウ酸、脂肪族カルボン酸及びそれらの塩並びにそれらの溶媒和物よりなる群から選ばれる1種以上である、[1]~[5]のいずれか記載の医薬製剤。
[7] 第4級アンモニウム型界面活性剤が、ベンザルコニウム塩化物及びベンゾドデシニウム臭化物よりなる群から選ばれる1種以上である、[1]~[6]のいずれか記載の医薬製剤。
[8] 多価アルコールが、グリセリン、ソルビトール、プロピレングリコール、マンニトール及びマクロゴールよりなる群から選ばれる1種以上である、[1]~[7]のいずれか記載の医薬製剤。
[9] プロスタグランジン類が、タフルプロスト、トラボプロスト、ビマトプロスト、ラタノプロスト及びそれらの塩並びにそれらの溶媒和物よりなる群から選ばれる1種以上である、[1]~[8]のいずれか記載の医薬製剤。
なお、斯かる態様の実施形態において、前記水性組成物に、酸類、第4級アンモニウム型界面活性剤、多価アルコール及びプロスタグランジン類よりなる群から選ばれる1種以上を含有せしめる工程と、前記水性組成物をポリオレフィン系樹脂製容器に収容する工程との先後は問わない。
[11] 前記一般式(1)で表される化合物が、前記式(2)、(5)、(5')又は(8)で表される化合物である、[10]記載の方法。
[12] 前記一般式(1)で表される化合物が、前記式(3)又は(6)で表される化合物である、[10]記載の方法。
[13] 前記一般式(1)で表される化合物が、前記式(4)又は(7)で表される化合物である、[10]記載の方法。
[14] ポリオレフィン系樹脂が、ポリエチレン又はポリプロピレンである、[10]~[13]のいずれか記載の方法。
[15] 酸類が、ホウ酸、脂肪族カルボン酸及びそれらの塩並びにそれらの溶媒和物よりなる群から選ばれる1種以上である、[10]~[14]のいずれか記載の方法。
[16] 第4級アンモニウム型界面活性剤が、ベンザルコニウム塩化物及びベンゾドデシニウム臭化物よりなる群から選ばれる1種以上である、[10]~[15]のいずれか記載の方法。
[17] 多価アルコールが、グリセリン、ソルビトール、プロピレングリコール、マンニトール及びマクロゴールよりなる群から選ばれる1種以上である、[10]~[16]のいずれか記載の方法。
[18] プロスタグランジン類が、タフルプロスト、トラボプロスト、ビマトプロスト、ラタノプロスト及びそれらの塩並びにそれらの溶媒和物よりなる群から選ばれる1種以上である、[10]~[17]のいずれか記載の方法。
また、以下の試験例において、HPLCを用いたネタースジルの測定は、カラムとしてODSカラムを、移動相として0.01モル/L リン酸緩衝液とアセトニトリルを、検出器として紫外吸光光度計(波長:254nm)をそれぞれ用いて行った。
ネタースジルのポリオレフィン系樹脂製容器への吸着の有無、及び吸着の抑制手段の検討のため、ネタースジルを含有する水性組成物にポリオレフィン系樹脂製の切片を共存させて一定期間保存した後の、水性組成物中のネタースジルの含量低下の有無を確認した。
すなわち、表1に示す各種の水性組成物を常法により調製した後、そのうち5mLをガラス容器に収容し、さらに、水性組成物にポリプロピレン(PP)製の樹脂切片3枚(それぞれ、1cm×2cmの大きさ)を浸漬させて、例1又は例2の医薬製剤を得た。また、別途、ポリプロピレン製の樹脂切片を浸漬させない以外は例2と同様にして、例3の医薬製剤を得た。
得られた各医薬製剤を、60℃で1週間保存した。保存後のネタースジルの含量低下の有無を確認するため、各医薬製剤における、保存前後の水性組成物中のネタースジルの濃度を測定した。水性組成物中のネタースジルの濃度は、HPLCを用いて、濃度既知のネタースジル溶液のピーク面積に対する水性組成物中のピーク面積の比率を測定することにより算出した。
そして、得られた水性組成物中のネタースジルの濃度より、以下の式に従い、ネタースジルの残存率(%)を評価した。
結果を表1に示す。
しかるところ、例1と例2との対比より、ネタースジルを含有する水性組成物に、さらにホウ酸を含有せしめることにより、ネタースジルの含量低下が抑制されることが明らかとなった。
水性組成物の処方を表2に示す通りに変更したほかは、試験例1と同様の方法により、試験を実施した。
結果を表2に示す。
水性組成物の処方を表3に示す通りに変更したほかは、試験例1と同様の方法により、試験を実施した。
結果を表3に示す。
水性組成物の処方を表4に示す通りに変更したほかは、試験例1と同様の方法により、試験を実施した。
結果を表4に示す。
水性組成物の処方を表5に示す通りに変更したほかは、試験例1と同様の方法により、試験を実施した。
結果を表5に示す。
水性組成物の処方を表6に示す通りに変更したほかは、試験例1と同様の方法により、試験を実施した。
結果を表6に示す。
ネタースジルの水性組成物中での熱に対する安定性を、高温条件下で一定期間保存後のネタースジルの含量低下の有無を確認することにより評価した。
すなわち、表7に示す処方の水性組成物を常法により調製した後、低密度ポリエチレン(LDPE)製、高密度ポリエチレン(HDPE)製、又はポリプロピレン(PP)製の容器に入れて、医薬製剤を製した。また、別途、同一の水性組成物をガラス製の容器に入れて、比較例の医薬製剤を製した。
得られた各医薬製剤を、80℃で1週間保存した。保存後のネタースジルの含量低下の有無を確認するため、試験例1と同様の方法により、各医薬製剤における、保存前後の水性組成物中のネタースジルの濃度を算出した。
そして、得られた水性組成物中のネタースジルの濃度より、以下の式に従い、ネタースジルの残存率(%)を評価した。
結果を表8に示す。
表9~表17に記載の成分及び分量(水性組成物100mL当たりの量(g))を含有する水性組成物を常法により調製し、これを高密度ポリエチレン製の点眼剤用容器に収容して、製造例1~36の医薬製剤を製造できる。
製造例1~36において、高密度ポリエチレン製の代わりにポリプロピレン製の点眼剤用容器を用いて、製造例37~72の医薬製剤を製造できる。
製造例1~36において、高密度ポリエチレン製の代わりに環状ポリオレフィン製の点眼剤用容器を用いて、製造例73~108の医薬製剤を製造できる。
製造例1~36において、高密度ポリエチレン製の代わりに低密度ポリエチレン製の点眼剤用容器を用いて、製造例109~144の医薬製剤を製造できる。
製造例1~144において、ネタースジル2メシル酸塩の代わりに、フリー体として0.5gのヴェロスジル1塩酸塩を用いたものを、製造例145~288の医薬製剤として、常法により製造できる。
製造例1~144において、ネタースジル2メシル酸塩の代わりに、フリー体として0.7gのヴェロスジル1塩酸塩を用いたものを、製造例289~432の医薬製剤として、常法により製造できる。
製造例1~144において、ネタースジル2メシル酸塩の代わりに、0.02gの式(8)で表される化合物を用いたものを、製造例433~576の医薬製剤として、常法により製造できる。
Claims (16)
- 次の成分(A)及び(B):
(A)下記の一般式(1)
R3は水素原子又はヒドロキシ基を示し、
Aは-CH(R4)-又は-CH2-CH(R4)-(ここでR4は置換基を有してもよいC6~C10アリール基、又は置換基を有してもよい5~10員のヘテロアリール基を示す。)を示し、
さらに、式(1)には、その互変異性体も含まれる。)
で表される化合物若しくはその塩又はそれらの溶媒和物;
(B)酸類、第4級アンモニウム型界面活性剤、多価アルコール及びプロスタグランジン類よりなる群から選ばれる1種以上;
を含有する水性組成物が、ポリオレフィン系樹脂製容器に収容されてなる、医薬製剤。 - 前記ポリオレフィン系樹脂が、ポリエチレン又はポリプロピレンである、請求項1~3のいずれか1項記載の医薬製剤。
- 前記酸類が、ホウ酸、脂肪族カルボン酸及びそれらの塩並びにそれらの溶媒和物よりなる群から選ばれる1種以上である、請求項1~4のいずれか1項記載の医薬製剤。
- 前記第4級アンモニウム型界面活性剤が、ベンザルコニウム塩化物及びベンゾドデシニウム臭化物よりなる群から選ばれる1種以上である、請求項1~5のいずれか1項記載の医薬製剤。
- 前記多価アルコールが、グリセリン、ソルビトール、プロピレングリコール、マンニトール及びマクロゴールよりなる群から選ばれる1種以上である、請求項1~6のいずれか1項記載の医薬製剤。
- 前記プロスタグランジン類が、タフルプロスト、トラボプロスト、ビマトプロスト、ラタノプロスト及びそれらの塩並びにそれらの溶媒和物よりなる群から選ばれる1種以上である、請求項1~7のいずれか1項記載の医薬製剤。
- 次の成分(A):
(A)下記の一般式(1)
R3は水素原子又はヒドロキシ基を示し、
Aは-CH(R4)-又は-CH2-CH(R4)-(ここでR4は置換基を有してもよいC6~C10アリール基、又は置換基を有してもよい5~10員のヘテロアリール基を示す。)を示し、
さらに、式(1)には、その互変異性体も含まれる。)
で表される化合物若しくはその塩又はそれらの溶媒和物;
を含有する水性組成物に、次の成分(B);
(B)酸類、第4級アンモニウム型界面活性剤、多価アルコール及びプロスタグランジン類よりなる群から選ばれる1種以上;
を含有せしめる工程と、前記水性組成物をポリオレフィン系樹脂製容器に収容する工程とを含む、前記一般式(1)で表される化合物若しくはその塩又はそれらの溶媒和物の前記水性組成物中での含量低下を抑制する方法。 - 前記ポリオレフィン系樹脂が、ポリエチレン又はポリプロピレンである、請求項9~11のいずれか1項記載の方法。
- 前記酸類が、ホウ酸、脂肪族カルボン酸及びそれらの塩並びにそれらの溶媒和物よりなる群から選ばれる1種以上である、請求項9~12のいずれか1項記載の方法。
- 前記第4級アンモニウム型界面活性剤が、ベンザルコニウム塩化物及びベンゾドデシニウム臭化物よりなる群から選ばれる1種以上である、請求項9~13のいずれか1項記載の方法。
- 前記多価アルコールが、グリセリン、ソルビトール、プロピレングリコール、マンニトール及びマクロゴールよりなる群から選ばれる1種以上である、請求項9~14のいずれか1項記載の方法。
- 前記プロスタグランジン類が、タフルプロスト、トラボプロスト、ビマトプロスト、ラタノプロスト及びそれらの塩並びにそれらの溶媒和物よりなる群から選ばれる1種以上である、請求項9~15のいずれか1項記載の方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020197028376A KR20190128657A (ko) | 2017-03-27 | 2018-03-27 | 의약 제제 |
CN201880021371.4A CN110494138B (zh) | 2017-03-27 | 2018-03-27 | 医药制剂 |
EP18775859.4A EP3603642B1 (en) | 2017-03-27 | 2018-03-27 | Pharmaceutical preparation |
KR1020237027391A KR20230125086A (ko) | 2017-03-27 | 2018-03-27 | 의약 제제 |
JP2019509877A JP7165123B2 (ja) | 2017-03-27 | 2018-03-27 | 医薬製剤 |
EP23204417.2A EP4285908A3 (en) | 2017-03-27 | 2018-03-27 | Pharmaceutical preparation |
JP2022166443A JP7469427B2 (ja) | 2017-03-27 | 2022-10-17 | 医薬製剤(2) |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017-060582 | 2017-03-27 | ||
JP2017060586 | 2017-03-27 | ||
JP2017060582 | 2017-03-27 | ||
JP2017-060585 | 2017-03-27 | ||
JP2017-060586 | 2017-03-27 | ||
JP2017060585 | 2017-03-27 | ||
JP2017-089205 | 2017-04-28 | ||
JP2017089205 | 2017-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018181294A1 true WO2018181294A1 (ja) | 2018-10-04 |
Family
ID=63676143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/012403 WO2018181294A1 (ja) | 2017-03-27 | 2018-03-27 | 医薬製剤 |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP4285908A3 (ja) |
JP (2) | JP7165123B2 (ja) |
KR (2) | KR20230125086A (ja) |
CN (1) | CN110494138B (ja) |
WO (1) | WO2018181294A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022120120A (ja) * | 2022-06-13 | 2022-08-17 | 東亜薬品株式会社 | 眼科用水性組成物及びプロスタグランジンF2α誘導体の含量の低下を抑制する方法 |
WO2023182480A1 (ja) * | 2022-03-25 | 2023-09-28 | 株式会社坪田ラボ | 水性組成物 |
JP7464675B2 (ja) | 2018-02-28 | 2024-04-09 | アルコン インク. | 医薬品製剤(2) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7108597B2 (ja) * | 2017-02-28 | 2022-07-28 | 興和株式会社 | 医薬品 |
KR20230128395A (ko) * | 2017-02-28 | 2023-09-04 | 코와 가부시키가이샤 | 의약 제제 |
CN110366416A (zh) * | 2017-02-28 | 2019-10-22 | 兴和株式会社 | 医药 |
RU2761625C2 (ru) * | 2021-02-11 | 2021-12-13 | Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") | Фармацевтическая композиция тафлупроста |
CN114796219A (zh) * | 2022-05-18 | 2022-07-29 | 沈阳药科大学 | 一种用于治疗青光眼的复方药物组合物及其用途 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1321144A1 (en) | 2000-09-13 | 2003-06-25 | Santen Pharmaceutical Co., Ltd. | Eye drops |
WO2005087237A1 (ja) * | 2004-03-16 | 2005-09-22 | Asahi Kasei Pharma Corporation | ファスジル含有製剤及びその安定性を改善する方法 |
JP2006249055A (ja) | 2005-02-08 | 2006-09-21 | Rohto Pharmaceut Co Ltd | プラノプロフェン含有医薬製剤 |
WO2009091898A2 (en) | 2008-01-17 | 2009-07-23 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
JP2012525386A (ja) | 2009-05-01 | 2012-10-22 | アエリエ・ファーマシューティカルズ・インコーポレーテッド | 疾患の治療のための二重機構阻害剤 |
JP5477996B2 (ja) | 2003-09-30 | 2014-04-23 | ロート製薬株式会社 | 透明包装体入りトラニラスト含有医薬製剤 |
WO2016047720A1 (ja) * | 2014-09-25 | 2016-03-31 | 興和株式会社 | 医薬品 |
JP2016515520A (ja) | 2013-03-15 | 2016-05-30 | アエリエ・ファーマシューティカルズ・インコーポレーテッド | 併用療法 |
JP2016138085A (ja) * | 2014-05-07 | 2016-08-04 | ロート製薬株式会社 | 包装体入り水性医薬製剤 |
EP3590514A1 (en) | 2017-02-28 | 2020-01-08 | Kowa Company, Ltd. | Medicinal preparation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050287325A1 (en) * | 2004-06-25 | 2005-12-29 | Pharmacia & Upjohn Company | Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients |
JP2008154810A (ja) * | 2006-12-25 | 2008-07-10 | Lion Corp | 眼科用剤 |
EP2127638A1 (en) * | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
CA2773597A1 (en) * | 2009-09-17 | 2011-03-24 | Senju Pharmaceutical Co., Ltd. | Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin |
CN106794186B (zh) * | 2014-09-25 | 2020-06-05 | 兴和株式会社 | 医药制剂 |
JP7108597B2 (ja) * | 2017-02-28 | 2022-07-28 | 興和株式会社 | 医薬品 |
CN110366416A (zh) * | 2017-02-28 | 2019-10-22 | 兴和株式会社 | 医药 |
-
2018
- 2018-03-27 WO PCT/JP2018/012403 patent/WO2018181294A1/ja unknown
- 2018-03-27 JP JP2019509877A patent/JP7165123B2/ja active Active
- 2018-03-27 CN CN201880021371.4A patent/CN110494138B/zh active Active
- 2018-03-27 KR KR1020237027391A patent/KR20230125086A/ko active IP Right Grant
- 2018-03-27 EP EP23204417.2A patent/EP4285908A3/en active Pending
- 2018-03-27 KR KR1020197028376A patent/KR20190128657A/ko not_active Application Discontinuation
- 2018-03-27 EP EP18775859.4A patent/EP3603642B1/en active Active
-
2022
- 2022-10-17 JP JP2022166443A patent/JP7469427B2/ja active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1321144A1 (en) | 2000-09-13 | 2003-06-25 | Santen Pharmaceutical Co., Ltd. | Eye drops |
JP5477996B2 (ja) | 2003-09-30 | 2014-04-23 | ロート製薬株式会社 | 透明包装体入りトラニラスト含有医薬製剤 |
WO2005087237A1 (ja) * | 2004-03-16 | 2005-09-22 | Asahi Kasei Pharma Corporation | ファスジル含有製剤及びその安定性を改善する方法 |
JP2006249055A (ja) | 2005-02-08 | 2006-09-21 | Rohto Pharmaceut Co Ltd | プラノプロフェン含有医薬製剤 |
WO2009091898A2 (en) | 2008-01-17 | 2009-07-23 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
JP2012525386A (ja) | 2009-05-01 | 2012-10-22 | アエリエ・ファーマシューティカルズ・インコーポレーテッド | 疾患の治療のための二重機構阻害剤 |
JP2016515520A (ja) | 2013-03-15 | 2016-05-30 | アエリエ・ファーマシューティカルズ・インコーポレーテッド | 併用療法 |
JP2016138085A (ja) * | 2014-05-07 | 2016-08-04 | ロート製薬株式会社 | 包装体入り水性医薬製剤 |
WO2016047720A1 (ja) * | 2014-09-25 | 2016-03-31 | 興和株式会社 | 医薬品 |
EP3590514A1 (en) | 2017-02-28 | 2020-01-08 | Kowa Company, Ltd. | Medicinal preparation |
Non-Patent Citations (26)
Title |
---|
"661 Containers-Plastics", THE UNITED STATES PHARMACOPEIA / THE NATIONAL FORMULARY, vol. 1, no. USP 35 / NF 30, 1 May 2012 (2012-05-01), pages 275 - 280, XP055862019, ISSN: 0195-7996 |
"Japanese Pharmaceutical Excipients Directory", 2016, YAKUJI NIPPO, LIMITED |
"Q1B Photostability Testing of New Drug Substances and Products", GUIDANCE FOR INDUSTRY, 1 November 1996 (1996-11-01), pages 1 - 11, XP055175855 |
ANONYMOUS: "RHOPRESSA (netarsudil ophthalmic solution) Label, NDA 208254, Reference ID:4194833", NDA 208254, no. ID: 4194833, December 2017 (2017-12-01), pages 4 - 10, XP055612923 * |
BACHARACH J. ET AL., OPHTHALMOLOGY, vol. 122, no. 2, 2015, pages 302 - 7 |
CASTELLANO A., J.P. CATTEAU, A. LABLACHE-COMBIER: "Mechanism of the photochemical substitution of 6-membered ring monoazaaromatic compounds by methanolin neurtral and HCI acidified medium", TETRAHEDRON, vol. 31, no. 18, 1 January 1975 (1975-01-01), pages 2255 - 2261, XP055862181 |
DEAN ET AL.: "Pharmaceutical Packaging Technology", 2000, pages: 459pp |
ELLIS, EYDIE MILLER ET AL.: "Ocular hypotensive effect of the novel EP 3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study", BRITISH JOURNAL OF OPHTHALMOLOGY, vol. 101, no. 6, 20 September 2016 (2016-09-20), pages 796 - 800, XP055538363, ISSN: 1468-2079 * |
EUROPEAN MEDICINES AGENCY (EMEA): "Note for Guidance on the Photostability Testing of New Active Substances and Medicinal Products", CPMP/ICH/279/95, 1 January 1998 (1998-01-01), pages 1 - 9, XP055459430 |
FDA: "LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution)", HIGHLIGHTS OF PRESCRIBING INFORMATION, 1 March 2012 (2012-03-01), pages 3 - 10, XP055862024 |
FDA: "XALATAN® (latanoprost ophthalmic solution) 0.005%", HIGHLIGHTS OF PRESCRIBING INFORMATION, 1 June 2014 (2014-06-01), pages 4 - 13, XP055862196 |
HILBORN J W, MACKNIGHT E, PINCOCK J A, WEDGE P J: "Photochemistry of Substituted Benzyl Acetates and Benzyl Pivalates: A Reinvestigation of Substituent Effects", J. AM. CHEM. SOC., vol. 116, no. 8, 1 January 1994 (1994-01-01), pages 3337 - 3346, XP055862188 |
JAMES SWARBRICK: "Encyclopedia of Pharmaceutical Technology, Third Edition", vol. 1, 1 January 2007, article MICHAEL J AKERS: "Drug Delivery: Parenteral Route", pages: 1266 - 1278, XP055649126 |
JAN F. RABEK: "Polymer Photodegradation Mechanisms and Experimental Methods", 1 January 1995, SPRINGER SCIENCE+ BUSINESS MEDIA, DORDRECHT, article "Photodegradation and photo-oxidative degradation ", pages: 3pp, 70, 84, XP055979466 |
LEVY, BRIAN ET AL.: "Ocular hypotensive safety and systemic absorption of AR -13324 ophthalmic solution in normal volunteers", AMERICAN JOURNAL OF OPHTHALMOLOGY, vol. 159, no. 5, May 2015 (2015-05-01), pages 980 - 985, XP055543404, ISSN: 0002-9394, DOI: doi:10.1016/j.ajo.2015.01.026 * |
PINCOCK JAMES A.: "Photochemistry of Arylmethyl Esters in Nucleophilic Solvents: Radical Pair and Ion Pair Intermediates", ACCOUNTS OF CHEMICAL RESEARCH, ACS, vol. 30, no. 1, 1 January 1997 (1997-01-01), US , pages 43 - 49, XP055862191, ISSN: 0001-4842, DOI: 10.1021/ar960177r |
REN, RUIYI ET AL.: "Netarsudil increases outflow facility in human eyes through multiple mechanisms", INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, vol. 57, no. 14, November 2016 (2016-11-01), pages 6197 - 6209, XP055538365, ISSN: 1552-5783, DOI: doi:10.1167/iovs.16-20189 * |
SINGH SHIVA P., STENBERG VIRGIL I., PARMAR SURENDRA S.: "Photochemistry of alkaloids", CHEMICAL REVIEWS, vol. 80, no. 3, 1 June 1980 (1980-06-01), US , pages 269 - 282, XP055862167, ISSN: 0009-2665, DOI: 10.1021/cr60325a004 |
STECK EDGAR A, EWING GALEN W: "Absorption Spectra of Heterocyclic Compounds. II. Amino-Derivatives of Pyridine, Quinoline and Isoquinoline", ABSORPTION SPECTRA OF PYRIDINES, QUINOLINES AND ISOQUINOLINES, vol. 70, no. 10, 1 October 1948 (1948-10-01), pages 3397 - 3406, XP055862186 |
STURDIVANT JM. ET AL., BIOORG MED CHEM LETT., vol. 26, no. 10, 2016, pages 2475 - 80 |
TONNESEN, H.H.: "Formulation and stability testing of photolabile drugs", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 225, no. 1-2, 28 August 2001 (2001-08-28), NL , pages 1 - 14, XP027379967, ISSN: 0378-5173 |
WILLIAMS RD. ET AL., AM. J. OPHTHALMOL., vol. 152, no. 5, 2011, pages 834 - 41 |
WU YI ., SHUAI YIN HUA DENG BIAN: "Pharmaceutical preparations biopharmaceutical production technology Books(Chinese Edition)", 1 June 2015, GUANGDONG HIGHER EDUCATION PRESS. , article "Pharmaceutical preparations biopharmaceutical production technology Books(Chinese Edition) /Passage/", pages: 93 - 97, XP055979450 |
Y. OHASHI ET AL.: "Ganka New Insight", vol. 2, 10 July 1997, article AWATA, TAKASHI: "Chapter II - Developing Eye Drop Medicines", pages: 15 - 25, XP055862164 |
ZHAO CHUNJIE: "Pharmaceutical Professional Knowledge 1", 1 January 2015, PEOPLE’S ARMY MEDICAL PRESS, article "Pharmaceutical Professional Knowledge 1 /Passage/", pages: 48 - 57, XP055979457 |
ZHU DAZHANG, WANG SHILONG, SUN XIAOYU, NI YAMING, YAO SIDE: "Reaction mechanism studies on isoquinoline with hydroxyl radical in aqueous solutions", FRONTIERS OF CHEMISTRY IN CHINA, vol. 2, no. 4, 1 October 2007 (2007-10-01), pages 354 - 358, XP055979428, ISSN: 1673-3495, DOI: 10.1007/s11458-007-0067-8 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7464675B2 (ja) | 2018-02-28 | 2024-04-09 | アルコン インク. | 医薬品製剤(2) |
WO2023182480A1 (ja) * | 2022-03-25 | 2023-09-28 | 株式会社坪田ラボ | 水性組成物 |
JP2022120120A (ja) * | 2022-06-13 | 2022-08-17 | 東亜薬品株式会社 | 眼科用水性組成物及びプロスタグランジンF2α誘導体の含量の低下を抑制する方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2023012481A (ja) | 2023-01-25 |
EP3603642B1 (en) | 2024-01-10 |
CN110494138A (zh) | 2019-11-22 |
CN110494138B (zh) | 2023-07-11 |
EP3603642A1 (en) | 2020-02-05 |
JP7165123B2 (ja) | 2022-11-02 |
KR20230125086A (ko) | 2023-08-28 |
KR20190128657A (ko) | 2019-11-18 |
JPWO2018181294A1 (ja) | 2020-02-06 |
JP7469427B2 (ja) | 2024-04-16 |
EP4285908A2 (en) | 2023-12-06 |
EP4285908A3 (en) | 2024-02-14 |
EP3603642A4 (en) | 2020-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7469427B2 (ja) | 医薬製剤(2) | |
JP2023041805A (ja) | 医薬品その5 | |
JP7045359B2 (ja) | 医薬製剤 | |
JP7455906B2 (ja) | 医薬(2) | |
JP5951921B1 (ja) | 組成物 | |
JP7449336B2 (ja) | 医薬品(2) | |
WO2016093346A1 (ja) | 水性組成物 | |
JP7191541B2 (ja) | 医薬製剤 | |
JP7165185B2 (ja) | 医薬品製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18775859 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019509877 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20197028376 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018775859 Country of ref document: EP Effective date: 20191028 |